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 HIV/AIDS is a global pandemic that has claimed the lives of 39 million people and currently 
afflicts 36.9 million more. These effects are disproportionately felt in sub-Saharan Africa which has 
almost 70% of those current cases and where women account for 59% of current infections. These 
numbers are even more disproportionate for young women and complications associated with HIV/AIDS 
are the leading cause of death in women aged 15-44. This creates a need for female-controlled tools to 
prevent infection. Microbicides are one such tool. 
 Microbicides are vaginally-delivered topical products that combine a therapeutic agent with 
activity against HIV and a delivery vehicle. The delivery vehicle can consist of many different 
formulations, depending on the therapeutic agent used and the delivery mechanism desired. Polymer 
solutions (known as “gels” in the microbicide field) have received the most attention and have been 
incorporated into the most formulations for use in clinical trial evaluations. There have been several high 
profile microbicide clinical trial failures, including nonoxynol-9 and cellulose sulfate, as well as one 
success, CAPRISA 004. Nonoxynol-9 failed in the direction of harm by producing host cell toxicity. The 
reasons for the failure of cellulose sulfate are not fully understood, but one hypothesis suggests 
unmeasured benefits provided by the delivery vehicle placebo caused the treatment arm to fail in the 
direction of harm. Conversely, CAPRISA 004 displayed moderate protection against HIV, which was 
highly correlated with adherence. The VOICE and FACTS 001 follow-up studies failed to prove the same 
efficacy, specifically citing low adherence as the reason for failure. These previous studies illustrate the 
need for delivery vehicles with fully understood physical properties that are safe, allow for effective 
microbicide delivery, and are acceptable to patients. 
 This study focused on rationally designing next generation microbicide delivery vehicles that are 
safe, effective, and acceptable. This rational design was accomplished using the methodology of 
computational molecular design (CMD). This process involves measuring relevant physical properties for 
a set of known compounds, creating structure-property correlations that relate these data to molecular 
structure, formulating an optimization problem that incorporates these correlations, and solving this 
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problem to generate novel structures that possess target physical properties. Novel delivery vehicles were 
designed to have ideal safety, efficacy, and adherence by creating a predictive model that considered 
rheology, biocompatibility, and drug compatibility. 
 Rheology describes the viscous and elastic character of a fluid. These properties influence the 
flow behavior of the fluid. The efficacy of liquid microbicide formulations depends upon the delivery 
vehicle flowing from the point of delivery to cover the entire epithelium to release the active therapeutic 
over this whole surface area as well as provide a lubricating barrier to pathogens. Additionally, patient 
acceptability and thus adherence is greatly influenced by how the fluid feels during insertion and use, 
what the consistency and color looks like, and whether the fluid leaks out prematurely. This study 
measured the rheology of a set of cellulose ethers, common liquid microbicide delivery vehicles, and 
related these data with molecular weight, molecular structure, and concentration to form the first part of 
the overall predictive model. 
 Biocompatibility characterizes the safety and incidence of harm to host cells caused by 
compounds. This study defined biocompatibility as in vitro vaginal cell cytotoxicity, inflammation 
represented as the upregulation of two cytokines, and inhibition of C. trachomatis infection. These 
properties were measured for the same set of cellulose ethers and correlated with molecular structure and 
molecular weight to form the second part of the overall predictive model. 
 Drug compatibility considers behavior of the active therapeutic in the delivery vehicle. This study 
defined drug compatibility as solubility of the drug in the delivery vehicle and release of the drug out of 
the delivery vehicle. Tenofovir, used in the successful CAPRISA 004 trial, was chosen as the model 
active therapeutic. The properties were again measured for the same set of compounds and correlated with 
molecular structure and molecular weight to form the final part of the predictive model. 
 This predictive model was finally incorporated into an optimization problem formulation along 
with structural feasibility constraints. Target properties for all the measured physical properties were 
selected and the optimization problem was solved to minimize the difference between the properties 
predicted by the model and these targets. This optimization process resulted in novel structures for 
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candidate delivery vehicles with improved properties compared to the measured set. These candidate 
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Pierce: […] of course we didn’t have the same safety standards back then so…no condoms. 
I tell ya, before AIDS sex was like shaking hands. 
 
Abed: Hence AIDS. 
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1.1 HIV/AIDS Problem 
 The HIV/AIDS pandemic remains a major global health concern (1). Since the identification of 
the disease in 1981, an estimated 39 million people worldwide have died from HIV/AIDS or assorted 
complications. About 14 million (2) of those deaths had occurred by the end of 1999, while 
approximately 25.3 million (3) people died between 2000 and 2014. At the end of 2014 (3), an estimated 
36.9 million people worldwide were living with HIV/AIDS and almost 51% were women. In that year 
(3), 2.0 million people were newly infected and 1.2 million died due to complications associated with the 
disease. This disease disproportionally affects the Global South with almost 70% of all HIV/AIDS cases 
occurring in sub-Saharan Africa, including 1.4 million new cases and 790,000 deaths (3). Collectively, 
those 44 countries have an adult prevalence of 4.8%, compared to a worldwide adult prevalence of 0.8% 
(3). The worst afflicted countries, such as Botswana, Lesotho, and Swaziland, had an adult prevalence 
around or above 25% (3). Although still formidable, these numbers indicated significant improvements in 
the global fight against HIV/AIDS in the last 15 years. 
 Great progress has been made since 2000. The worldwide new infection rate has declined 35% 
since 2000, from 3.1 million that year to 2.0 million in 2014 (3). The yearly death rate has decreased 42% 
from its peak in 2004, from 2.0 million in 2005 to 1.2 million in 2014 (3). In sub-Saharan Africa during 
this period new infections were down 41% and AIDS-related deaths decreased by 48% (3). These 
advances are due to a plethora of HIV/AIDS treatment and prevention strategies, in particular the increase 
in access to antiretroviral drugs. In 2000, only about 10,000 of those infected with HIV/AIDS in sub-
Saharan Africa had access to HIV antiretroviral medicines with a yearly cost of $10,000 (US) (3). 
Worldwide, those living with HIV/AIDS who have access to antiretroviral therapy have risen from 1 
million in 2001 to over 15 million in 2015, and first-line treatment regimens are only $100 (US) (3). 
Without increased access to antiretroviral and prevention techniques, it is hypothesized that 30 million 
more people would have been infected in the 15 year period from 2000 to 2015, and that 7.8 million more 
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would have died (3). Even with these key advancements several populations, most notably young women, 
are being left behind. 
 Worldwide, women account for just over half of all HIV/AIDS cases, but in sub-Saharan Africa 
they are nearly 59% of the currently infected (3). Women are more biologically susceptible to HIV 
infection when exposed to the virus to due differences in reproductive anatomy and fluid transfer during 
intercourse (4). The statistics become particularly stark for young women. In sub-Saharan Africa, among 
young people aged 15-24 currently infected with HIV/AIDs, 63% are women (3). For adolescents the 
prevalence is 1.7 times higher for females compared males, and in South Africa the prevalence is eight 
times higher for females aged 15-19 compared to males (5). The new infection rate continues to 
disproportionally impact young women. Worldwide, females account for 56% of new infections among 
15-24 year olds and 62% among 15-19 year olds. In sub-Saharan Africa these figures increase to 64% and 
71%, respectively (6). In South Africa, new infections for young people aged 15-24 are four times higher 
for females compared to males (7). HIV/AIDS-related illnesses are the leading cause of death worldwide 
for women of reproductive age (15-44 years), and also the leading cause of death for adolescent (10-19 
years) females in sub-Saharan Africa. These disparities in HIV infection vulnerabilities are due to gender 
inequalities and inadequate prevention programs. 
 Current prevention programs include condom use, voluntary medical male circumcision 
(VMMC), needle-syringe programs, opioid substitution therapy for injection drug users, and antiretroviral 
treatment. VMMC provides a 60% reduction in female-to-male HIV transmission, comparable to vaccine-
like levels (8). Needle-syringe programs that decrease the use of unsterile injection equipment decrease 
HIV transmission (9). Opioid substitution therapy reduced HIV incidence by an average of 54% among 
intravenous drug users across nine studies (10). Antiretroviral treatment, if begun as soon as a person is 
diagnosed, can reduce HIV transmission to a partner by 96% (11). Condom use continues to be the main 
prevention tool (12). There have been significant gains in regional availability, with 1.7 billion condoms 
procured for sub-Saharan Africa in 2014, compared to 0.4 billion in 2001 (3). However, this increase 
amounts to only eight condoms available per year for each sexually active individual in sub-Saharan 
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Africa (3), hardly enough to confer complete protection against HIV/AIDS. Indeed, in 2014 (3) only one 
out of every three women with multiple sexual partners reported using a condom the last time they had 
sex. Women are much less likely than men to use condoms in non-marital relationships, and men are less 
likely to know their HIV status since they are more likely to avoid being tested for HIV compared to 
women (13). Thus women struggle to access prevention tools, especially young women, and social 
inequalities prevent them from consistently using these methods. 
 Many barriers of access prevent young women from effectively protecting themselves from 
HIV/AIDS. Gender inequalities, such as power inequalities in relationships and intimate partner violence, 
place women at a great risk of HIV exposure compared to men (14, 15). For instance, modeling in Kenya 
suggests that solely eliminating sexual violence could prevent 17% of HIV infections for sex workers 
(16). Often, women do not have autonomy to make decisions about their health care and sexual practices. 
The number of women who do not have these choices in sub-Saharan Africa is over 50%, and in some 
countries as high as 70-80% (17). When available to women, various treatment options either confer 
benefits to men or are male-controlled. VMMC protects men (8); men predominately decide if and when 
to have sex and whether to use a condom (17); HIV-positive men are less likely to receive antiretroviral 
treatment compared to women, and men who are treated are less likely to adhere to antiretroviral therapy, 
thus putting their partners at risk (18). For all of these reasons young women urgently need a new, female-
controlled prevention tool. One such tool, which depends upon a woman’s decision instead of the male 
partner’s, is vaginal gel microbicides. 
1.2 A Review of Anti-HIV Microbicides in Development 
Microbicides (19-22) are vaginally- (23) or rectally- (24) delivered topical products that prevent 
against sexually transmitted infections, or STIs. A complete formulation combines an active therapeutic 
and/or prophylactic agent, known as an active pharmaceutical ingredient (API), with a delivery vehicle, 
sometimes referred to as a drug delivery system (DDS). The delivery vehicle can consist of a polymer 
solution (often known as a “gel” in the microbicide field), cream, film, diaphragm, ovule, intravaginal 
ring, implant, injection, oral tablet, or quick dissolving tablet. Different types of delivery vehicles have 
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different mechanisms of protection. Delivery vehicles can either provide chronic, low doses of API for 
long-term protection, or brief, high doses for short-term or emergency protection (25). Both delivery 
mechanisms have strengths and drawbacks. 
Long term delivery mechanisms remain in the same site for an extended period of time from 
which they produced a continuous release of the API. Long term delivery vehicles require less frequent 
dosing than short term mechanisms. Typically new doses are applied once a month or every few months. 
This strategy involves less effort from patients who do not have to adhere to a strict daily dosing 
schedule. Various delivery vehicles can confer this long term delivery.  Subdermal injections (26-28) 
consist of a liquid suspension of the API. Low systemic concentrations from the injection and very short 
API residence times at active sites have provided challenges to this delivery mechanism (29). Integration 
of the API in a nanoparticle can produce constant, sustained release over the course of a month as the 
nanoparticle breaks down, and thus improve the efficacy of this delivery mechanism (30). Subdermal 
implants are modeled on the long-acting contraceptive implants (31), such as Norplant ® (32). These 
delivery systems confer protection in much the same way as a nanoparticle injection. The API is released 
at constant rate out of the polymer implant for a sustained period of time (33). A microbicide-loaded 
diaphragm provides an option for dual HIV-protection and contraception (34). The delivery vehicle is 
placed over the cervix as with a standard diaphragm and remains in place for up to six months while it 
releases a steady concentration of anti-HIV API. Vaginal ovules or suppositories (35, 36) are similar to 
commercial products that treat common vaginal infections. These delivery vehicles are similar to 
subdermal implants except they are applied directly to the surface of the upper vaginal tract. The benefit 
of these delivery vehicles is that they release a constant dose of API right at the site of infection 
challenge, rather than systemically. In recent years, two forms of long term protection have received a lot 
of attention. These include intravaginal rings and oral tablets. 
As with the subdermal implants and intravaginal diaphragms, intravaginal rings for microbicide 
delivery (37) are modeled on contraceptive rings such as NuvaRing® (38), Progering® (39), and 
Fertiring® (40), and estrogen replacement therapy such as Estring® (41) and Femring® (42). These rings 
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are usually made from silicone elastomer, with the exception of NuvaRing® which is vinyl acetate and 
ethylene copolymer (43). These rings are inserted into the upper vaginal tract where they remain in place 
for 30 days, releasing a constant concentration of API (44). A large number of HIV antiretroviral 
microbicides have been formulated into these delivery vehicles (45, 46) and several are undergoing 
clinical trials (44), including a completed Phase I safety trial of a dapivirine (DPV) and maraviroc (MVC) 
combination (47), an a Phase I trial of a tenofovir (TFV) and levonorgestrel (LNG) combination HIV 
microbicide and contraceptive, respectively (47). Most notably was the ASPIRE trial, a Phase III safety 
and efficacy trial of a vaginal ring containing DPV (48). The results displayed a 27% reduction in HIV 
infections in the treatment arm compared to the placebo (49). When two test sites with low adherence 
were removed, the reduction in infection increased to 37%. Further, a 56% reduction in infection was 
observed for women over 21 years old while no reduction was seen in women under that age. The 
disparity between these figures was correlated with adherence. Although the overall benefit conferred by 
this study was low, these results, especially the increased protection found in those individuals with high 
adherence, are encouraging for the development of future microbicides. 
Finally, oral tablets provide pre-exposure prophylaxis, known as PrEP, with daily dosing of 
antiretroviral drugs for HIV-negative individuals with HIV-positive partners (50). Daily dosing provides a 
steady, systemic concentration of the API. In 2012 the FDA approved a combination dose of tenofovir 
disoproxil fumarate (TDF) and emtricitabine (FTC), known as Truvada®, for use by sexually active, 
HIV-negative adults to prevent infection (51). This followed two large scale clinical trials supporting the 
efficacy of this dosing regimen. The iPrEx trial enrolled high risk men who have sex with men (MSM) 
and the overall efficacy was 44% (52). Although lower than expected, the rate of efficacy was highly 
dependent upon adherence such that the group with 90% adherence displayed 73% efficacy. The Partners 
PrEP trial observed heterosexual serodiscordant couples where one partner was HIV-infected and the 
other was not (53, 54). This trial observed much higher adherence overall such that the overall prevention 
efficacy was 73%. These results are highly encouraging and provide another prevention tool in addition to 
traditional prophylactic methods.  
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Conversely to the above delivery vehicles, short term formulations require dosing immediately 
before sexual intercourse and must be used repeatedly for each act. This requires more effort on the part 
of the patient (55). However, these vehicles can deliver a higher dose of the API at the site of infection 
during the period of viral challenged compared to long-term delivery vehicles. Short term delivery 
vehicles include gels (56-62), creams (63), films (64-70), and quick dissolving tablets (70-73). Similar to 
other delivery vehicles, these mechanism are based on current commercial products (74), such as vaginal 
contraceptive films (VCF) (75), Vagistat-1® tablets for yeast infections (76), or KY® Jelly for vaginal 
lubrication (77). Vaginal gels and creams are liquid formulations that are inserted with an applicator in 
the upper vaginal tract and then spread or flow to cover the entirety of the vaginal epithelium (78). Quick 
dissolving films and tablets are solid or semi-solid formulations that are inserted into the vaginal tract and 
quickly absorbed into the epithelium (70). These short term delivery vehicles have received a high 
amount of attention over the past few decades as possible ant-HIV vaginal microbicides, with variable 
rates of success. 
1.3 History of Vaginal Gel Microbicides 
The first vaginal microbicides clinically evaluated had non-specific inhibitory activity against 
HIV and other STIs. This class of microbicides were surfactants (79). Surfactants non-specifically destroy 
the integrity of lipid bilayers and thus kill cells through membrane rupture and inactivate viruses by 
disrupting the viral envelope. One such surfactant, nonoxynol-9 (N9), had been used since the 1960s as a 
lubricating contraceptive spermicide that was later used to coat latex condoms (80). The antiviral 
capabilities of N9 were recognized as early as 1985 (81), and the compound displayed good efficacy 
against HIV in vitro (82), and in vivo (83). However, clinical trials of N9 failed to prove efficacy. Early 
trials of sex workers in Kenya (84) and Cameroon (85) displayed no difference in infection rates between 
the treatment and placebo arms. However those treated with N9 had a higher incidence of genital 
ulcerations. In addition to failing to prove efficacy, a phase III trial of sex workers in four countries 
displayed an almost double HIV infection rate in the N9 arm compared to placebo in women who used 
the formulation more than three times a day (86, 87). The increase in vaginal toxicity, ulcerations, and 
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inflammation at higher doses was suggested as the cause of increase in infection rate (88). Thus N9 was 
discontinued from microbicide development and greater emphasis was placed on safety studies before 
clinical scale-up. Another surfactant, cetyl betaine and myristamine oxide (C31G), had similar antiviral 
activity to N9 but was assumed less cytotoxic (89). In 2005 and 2006 two trials (90) of C31G were halted 
for futility. The HIV infection rate was lower than anticipated and thus statistical significance could not 
be determined. Although it was not significant, there was a trend towards higher infection rates among the 
treatment arm compared to the placebo. Due to these results other classes of microbicides have been 
increasingly explored. 
A second class of non-specific microbicides are vaginal milieu protectors (91). These prevent 
infection by restoring or enhancing the natural protective mechanisms inherent within the vaginal canal, 
particularly by maintaining the acidic pH produced by native lactobacilli. A healthy vaginal pH is in the 
range of 3.5 to 4.5, while HIV is inactivated at a pH between 4.0 and 5.8 (92). However, the presence of 
semen and some disease states neutralizes this acidity, allowing for viral penetration. One such acidifying 
agent is Carbopol 974P, or BufferGel. BufferGel is a polyacrylic acid that buffers twice its volume of 
semen to below pH 5 (93). BufferGel is spermicidal and has activity against HIV, HSV, HPV, bacterial 
vaginosis, and Chlamydia trachomatis (94). Although BufferGel was found safe in two phase I trials (95, 
96), a phase II trial failed to prove efficacy over a placebo gel or no gel (97). 
A final class of non-specific microbicides is anionic polymers that function as viral entry 
inhibitors (98). These negatively charged molecules interact with the positively charged proteins on the 
HIV viral envelope and prevent attachment of HIV to CD4+ cells (99). A sulfonated polymer, 
naphthalene sulfonate, known as PRO 2000, has in vitro activity against HIV, HSV, C. trachomatis, and 
Neisseria gonorrhoeae (100). Phase I clinical trials indicated safety of the formulation (101), although 
high concentrations were associated with increased intermenstrual bleeding (102). Early phase II efficacy 
trials demonstrated a moderate, statistically nonsignificant 30% reduction in HIV infection conferred by 
PRO 2000 (97). A phase III trial demonstrated safety but not efficacy (103, 104). Another sulfonated 
polysaccharide derived from seaweed, carrageenan, known as Carraguard, blocks HIV infection by 
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binding to the viral envelop and preventing HIV-infected mononuclear cells from migrating across the 
vaginal epithelial surface to lymph nodes (105). Once again, although this formulation was safe in early 
trials (106, 107), phase III trials failed to prove efficacy over the placebo (108). However, applicator dye 
testing indicated that adherence was low, only 42%, which might have contributed to the negative 
outcome. A final anionic polymer considered in large scale clinical trials was cellulose sulfate. In addition 
to HIV, cellulose sulfate has in vitro activity against HPV, N. gonorrhoeae, C. trachomatis, and 
Gardnerella vaginalis (109). However, after successful phase I safety studies (110, 111), in 2007 two 
large phase III trials in Africa and India had to be halted after one of them displayed 50% higher HIV 
infection in the cellulose sulfate arm compared to the placebo (112). As of today no satisfactory 
explanation exists as to why cellulose sulfate failed in the direction of harm (112). One hypothesis states 
that microscopic harm induced by cellulose sulfate to lactobacilli caused an inflammatory response and 
microscopic vaginal lesions that promoted HIV diffusion (113). Another hypothesis suggests that an 
unmeasured property of the placebo delivery vehicle provided non-specific benefit to the patient. The 
placebo could non-specifically reduce HIV infection and other STIs by non-specifically binding to 
pathogens, preventing pathogen diffusion through the delivery vehicle to the epithelial surface, and 
providing lubrication that prevents trauma and irritation to the vaginal epithelium and thus promotes the 
body’s natural infection defenses (114). These failures create a need for both more specific APIs to 
prevent HIV infection that do not harm native tissues and for a more complete understanding of delivery 
vehicles and corresponding placebos. 
In recent years there has been a shift from non-specific APIs to APIs with specific activity against 
HIV. This class of microbicides is antiretroviral (ARV) agents which work by preventing viral host cell 
entry or viral replication. These include CCR5 inhibitors, fusion inhibitors, and reverse transcriptase 
inhibitors (RTIs). CCR5 inhibitors target the CCR5 co-receptor located on human macrophages and thus 
prevent viral entry into host cells (115). Several APIs of this type have undergone preclinical evaluation, 
including maraviroc (116), and PSC-RANTES (117). Fusion inhibitors, such as cyanovirin-N (118), 
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inhibit viral envelope protein-mediated viral-cell fusion and thus prevent HIV from entry target cells 
(119). However, by far the most promising ARV class for microbicide development is the RTIs. 
RTIs inhibit HIV infection by preventing reverse transcription of viral RNA and thus halt viral 
replication (120). RTIs cross host cell membranes of HIV infected cells and bind to the HIV reverse 
transcriptase enzyme. This blocks the conversion of viral RNA into DNA, which in turn prevents 
integration of this viral DNA into the host DNA, which would prompt replication of viral proteins. RTIs 
under consideration as vaginal microbicides include dapivirne, UC781 (121), TMC 120 (122), DABOs 
(123), and pyrimidinediones (124). The most widely studied of all the RTIs for the purpose of creating 
vaginal microbicides is tenofovir. 
Tenofovir was one of the first ARV drugs evaluated for pre- and post-exposure prophylaxis in 
animal models (125). Successful inhibition of HIV in these models allowed tenofovir to be the first ARV 
assessed as a vaginal microbicide in clinical trials (126, 127). In 2010 results were released for the 
CAPRISA 004 randomized trial, the first microbicide trial to display efficacy over the placebo (128). 
CAPRISA 004, a 1% tenofovir gel, reduced HIV 39% overall in the treatment arm compared to the 
placebo. Efficacy was highly correlated with adherence. Those individuals with high adherence, greater 
than 80%, had a 54% reduction in infection. Conversely, those with moderate adherence, 50 to 80%, had 
a 38% reduction in infection, while those with low adherence, less than 50%, had only a 28% reduction in 
infection. Still, these results were very promising. However, follow-up studies have not been able to 
replicate these results. The 2013 VOICE study (129), which looked at oral daily treatment of TDF, oral 
daily treatment of TDF-FTC, or a 1% tenofovir gel as PrEP, failed to display efficacy in any treatment 
arm, although the infection rate was lowest for the TFV gel. Low adherence was specifically cited as the 
reason for the trial failure. The FACTS 001 trial (130), which assessed a 1% tenofovir gel for women 
aged 18-30, also failed to prove efficacy. Once again adherence was low and gel effectiveness was 
highest in the most adherent subgroup. 
These variable successes and failures of microbicide clinical trials emphasize the need for safe 
and effective microbicide formulations. Neither the API nor the delivery vehicles should cause harm 
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during repeated use over long periods of time. Further, the delivery vehicle and placebo should be fully 
characterized for any potential harms or benefits that could impact efficacy of the microbicide. Finally, a 
formulation must be acceptable to the patient to maximize patient acceptability and thus to maximize 
efficacy. Additionally, a microbicide formulation should ideally prevent other STIs, such as Chlamydia 
trachomatis, which increase HIV transmission and acquisition as co-current infections. 
1.4 Chlamydia trachomatis Infection and HIV 
 Chlamydia trachomatis is the most prevalent sexually transmitted bacterial infection worldwide 
(131). In 2012 alone there were an estimated 131 million new cases (131). C. trachomatis causes severe 
infections of the mucosal epithelium in the genital tract. These include urethritis, cervicitis, epididymitis 
(132), and lymphogranuloma venereum (LGV) (133), an invasive infection that spreads via macrophages 
to the lymph nodes. Women suffer the most severe consequences of C. trachomatis infection, with an 
estimated 10-15% of untreated infections progressing to the uterus or fallopian tubes to cause pelvic 
inflammatory disease (PID) (134). Complications of PID include chronic pelvic pain, life-threatening 
ectopic pregnancy, and tubal factor infertility (135). Additionally, C. trachomatis infection increases rates 
of HIV transmission and acquisition. 
 C. trachomatis infection can increase the risk of HIV infection when exposed to the virus and 
also increase HIV transmission to partners (136-139). As part of the normal host response to infection, C. 
trachomatis infection activates recruitment of HIV infected inflammatory cells to the genital tract 
mucosal surface. This increases HIV shedding in the genital tract and increases viral loads in cervical 
fluid and semen (136, 137). Patients with both HIV and C. trachomatis infections have higher viral loads 
and are thus more infectious compared to patients only infected with HIV (140). The recruitment of 
inflammatory cells to the epithelial surface also increases infection susceptibility in HIV-negative patients 
when challenged by the virus. C. trachomatis infection recruits leukocytes to the genital tract and 
interacts with these leukocytes to increase HIV viral replication in infected cells present in the partner’s 
semen or cervical fluid (141). Thus, preventing and treating genital C. trachomatis infection serves as a 
prevention mechanism against HIV transmission and acquisition. 
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 C. trachomatis is an obligate intracellular parasite and exists in two morphological forms, 
infectious, metabolically inactive elementary bodies (EBs) and noninfectious, metabolically active 
reticulate bodies (RBs) (142). Infection is caused by attachment of an EB to a host cell surface and 
subsequent internalization into the cell (143). Following internalization the EBs transition to RBs and 
undergo replication via binary fission (142). Upon completion of the development cycle the RBs 
differentiate back to EBs and are released from the cell either by cell lysis or as a packaged extrusion 
(144). The infection process continues again in neighboring cells. Thus, a microbicide that inhibited entry 
of the EBs into host cells would halt this process, prevent C. trachomatis infection, and help prevent 
subsequent HIV infection and transmission. 
 Microbicide APIs are often assessed for their activity against several STIs in addition to their 
anti-HIV activity. As discussed in the preceding section, cellulose sulfate (112), Carraguard (145), and 
PRO 2000 (103) have all been evaluated for their activity against C. trachomatis. However, since C. 
trachomatis is an intracellular parasite, infection can be prevented by preventing bacterial entry into host 
cells. Thus the microbicide delivery vehicle itself could provide activity against C. trachomatis. Indeed, 
several studies have demonstrated in vitro anti-chlamydial activity of compounds used in anti-HIV 
microbicide delivery vehicles (146, 147). In particular, one study of hydroxyethyl cellulose, a major 
component of the CAPRISA 004 microbicide and placebo, demonstrated inhibition of C. trachomatis 
infection in HeLa 229 cervical epithelial cells (148). A collaborator on this dissertation, Ichie Osaka, 
further demonstrated the inhibitory ability of this hydroxyethyl cellulose as well as several other types of 
cellulose ethers, which are structurally similar (149). This work further emphasizes the need to fully 
characterize the anti-bacterial and anti-viral activities of delivery vehicles that would confer added anti-
STI activity to the microbicide formulation and thus increase anti-HIV activity by decreasing co-
infections.  
1.5 Properties of Ideal Microbicides 
The NIH National Institute of Allergy and Infectious Diseases (NIAID) research topic on 
HIV/AIDS defines the optimal characteristics of a microbicide (150, 151). As mentioned above, the 
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microbicide formulation must be safe for use over extended periods of time whether it is used repeatedly 
daily, periodically, or occasionally. The formulation cannot cause harm to the host. Thus the formulation 
cannot exhibit toxicity to host cells, promote an inflammatory response, disrupt the vaginal epithelium or 
microbiota, or otherwise irritate the vaginal mucosal environment (152). While all microbicide 
formulations must be safe for repeated and extensive use, those formulations that confer repeated short 
term protection directly to the vagina require special consideration. Marginal irritations can accumulate 
over time and cause adverse effects, as seen with the surfactant microbicides. Micro-abrasions that are not 
visible during routine pelvic exams can still facilitate viral diffusion and HIV infection (153). These 
properties must be shared by both the API and the delivery vehicle. 
The API must be effective against HIV infection. In order for the API to be effective, the delivery 
vehicle must release and deliver the API quickly to the proper site of action in the host tissues at the 
desired dose level. The delivery vehicle must be retained at the site of action for a sufficient period of 
time to allow for thorough API release. The delivery vehicle has another requirement to create an 
effective microbicide formulation. The delivery vehicle must solubilize a sufficient concentration of the 
API and then release the proper dose to the proper site in the body depending on the API’s method of 
action. Additionally, it is desirable for the microbicide, whether API, formulation, or both, to have 
additional activity against STIs associated with increased HIV infection, such as C. trachomatis. 
The microbicide must be acceptable to the user and their partner. The formulation should not be 
unpleasant to use nor decrease pleasure. The microbicide should not produce an unpleasant odor, have an 
undesirable color, or produce an uncomfortable sensation that would prevent a patient from using it (154). 
If the microbicide is prepared in a liquid formulation it must coat the vaginal epithelium, it must not have 
an unpleasant consistency, it must not leak prematurely, it must not be messy, and it must not change 
consistency or color during coitus (155, 156). If these property requirements are not met, the microbicide 
will be unacceptable to the patient and adherence will decrease, which in turn will decrease the efficacy of 
the API. To provide the required safety, efficacy, and acceptability, anti-HIV vaginal microbicides and 
their delivery vehicles must possess a number of optimal physical, chemical, and biological properties. 
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Next generation APIs and delivery vehicles should be rationally designed at the pre-clinical stage to 
ensure the formulation of microbicides that possess all of these properties to prevent future clinical 
failures. This rational design can be achieved with computational molecular design (CMD). 
1.6 Computational Molecular Design 
CMD (157) is an optimization methodology that generates products with near-optimal behavior 
by relating that behavior empirically to physical or chemical properties, and relating those physical and 
chemical properties to the molecular structure. Novel products are proposed by incorporating these 
correlations into an optimization problem formulation, and then solving the problem to generate structures 
that correspond to ideal properties and behavior. In brief, the process involves the creation of a model 
building set of test compounds, generation of structure-property correlations, development and solution of 
an optimization problem, and synthesis of novel molecules.  
A complete CMD problem is solved using the following steps. First, a set of compounds, known 
as a model building set, with known molecular structures are selected. The relevant physical or chemical 
properties, corresponding to some desired behavior, of these compounds are then measured. At the same 
time structural descriptors, which numerically describe the molecular structure, are calculated for the 
compounds. These measured data and calculated structural descriptors are then incorporated into 
quantitative structure-property relationships (QSPRs), which are empirical equations that predict physical 
properties given molecular structure (158). These QSPRs are integrated into an optimization problem 
formulation along with a number of structural feasibility constraints to ensure chemically possible 
molecules are generated. This problem is solved to generate several novel molecular structures that 
possess the target physical properties that correspond to the desired behavior. CMD is an advantageous 
methodology because multiple properties and behaviors with conflicting targets can be considered within 
one problem. This problem can be solved quickly multiple times to produce many candidate molecules 
and thus accelerate the timeline of drug discovery and pre-clinical evaluation by minimizing the need for 
high-throughput screening. 
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CMD has been used in many pharmaceutical fields including drug discovery, protein 
characterization, and polymer drug delivery system design. This methodology can predict pharmaceutical 
properties such as solubility and permeability (159-163) to streamline high-throughput screening in drug 
discovery. Protein-ligand interactions (164-168) can be predicted to aid in design of more targeted drugs. 
New enzymes can be designed to catalyze reactions that lack naturally occurring biocatalysts (169-172). 
CMD can predict protein structure, folding, and stability from peptide sequence and protein secondary 
structure (173-176). Aggregation propensity can be predicted from protein structure (177-179). CMD can 
design cross-linked polymers for improved dental restorations (180) and controlled release hydrogel 
formulations (181). CMD accelerates the discovery and development of novel molecules and 
formulations, and therefore is useful for the design of microbicide delivery systems. This dissertation 
broadens both the fields of microbicides and CMD by using this computational methodology in a unique 
manner to design novel delivery vehicles for a specific microbicide API possessing the characteristics of 
an ideal microbicide. 
1.7 Project Summary 
 This dissertation will use CMD to rationally design next generation delivery vehicles for a gel 
formulation of tenofovir that possess ideal safety, efficacy, and acceptability characteristics. Chapter 2 
will assess the rheology for a model building set of delivery vehicles and relate these measurements to 
molecular structure in a set of QSPRs. The rheology of gel delivery vehicles influences their spreading 
behavior. This spreading behavior, in turn influences the efficacy of the formulation by providing a 
prophylactic barrier for the vaginal epithelium and determining the surface area of drug release. Further, 
patient acceptability depends upon how the delivery vehicle flows when applied and whether it is retained 
or leaks out. 
Chapter 3 will assess safety for the same model building set of delivery vehicles and relate them 
to molecular structure in a set of QSPRs. Safety will be defined as in vitro cytotoxicity, upregulation of 
cytokine production that induces an inflammatory response, and inhibition of C. trachomatis. 
Cytotoxicity is measured using an alamarBlue® assay, which indicates cell viability by measuring aerobic 
15  
respiration. Solutions containing the delivery vehicles are applied to the surface of plated cells and 
incubated for a period of time, after which the impacts of the delivery vehicles on cell viability are 
compared to cells incubated with no delivery vehicle (182). Inflammation is measured as the upregulation 
of cytokines IL-6 and IL-8 using ELISA kits. Solutions containing the delivery vehicles are applied to the 
surface of plated cells and incubated for a period of time, after which the cell supernates are collected and 
the quantities of cytokines produced are measured using sandwich ELISA plates and compared to positive 
and negative controls (183). Inhibition of C. trachomatis infection conferred by the delivery vehicles is 
measured using a direct culture infection. Solutions containing the delivery vehicles and infectious C. 
trachomatis are applied to the surface of plated cells and incubated for a period of time and then removed. 
The cells are then fixed with methanol, stained, and enumerated for amount of C. trachomatis infection, 
which is compared to a negative control containing no delivery vehicle in the infectious media (184). 
A variety of in vitro methods exist to assess cellular cytotoxicity. One mechanism measures cell 
membrane integrity to determine cell viability. These assays include trypan blue (185), and lactate 
dehydrogenase (LDH) (186). Cell viability can also be assessed by measuring overall cell metabolic 
activity to determine if compounds harm cells in ways other than membrane rupture. These assays include   
MTT (187) and alamarBlue® (182), which measure the overall reducing potential of cells. AlamarBlue® 
was chosen for this dissertation because this assay quantifies other types of metabolic harm in addition to 
membrane disruption. Many different safety biomarkers have been considered to assess preclinical 
inflammation, including many different cytokines and chemokines (188-192). In particular, IL-6 and IL-8 
have been identified as playing important roles in the inflammatory pathways that recruit HIV target cells 
and have been suggested as good predictors of epithelial inflammation for evaluating vaginal 
microbicides (182, 193, 194). For these reasons they were chosen as the pro-inflammatory cytokines 
measured in this dissertation. Finally, in vitro assays of C. trachomatis infection typically rely on staining 
the chlamydial inclusion followed by direct enumeration via manual, visual inspection under a 
microscope (195). The above assay method (184) was selected for its adaptability to a high-throughput 
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screening format, a methodology that is advantageous when testing the many compounds that constitute a 
model building set. 
Chapter 4 will conclude this work by measuring drug compatibility, generating the final set of 
QSPRs, and performing the final optimization. Delivery vehicles can promote drug efficacy by promoting 
compatibility with the API. This study defines drug compatibility as drug solubility in the delivery 
vehicle and drug release from the delivery vehicle. Drug solubility is assessed by performing incubator 
shaker tests. An excess of drug powder is added to solutions containing the delivery vehicles and then 
shaken at a constant temperature for a period of time, after which the concentration in the sample is read 
using an HPLC column (196). Drug release is assessed by measuring drug diffusion out of a dialysis bag. 
Solutions containing the delivery vehicle and drug are placed inside a dialysis bag which is incubated and 
shaken for a period of time. The drug diffuses through a semi-permeable dialysis membrane, which 
allows the drug molecules to pass but not the delivery vehicle molecules, and into a receiving medium. 
The final concentration of drug in this receiving medium is measured using an HPLC column (197). 
To assess aqueous solubility, incubator shaker tests are standard protocol for the NIH, NIEHS, 
and EPA (198). The above method (196) combines this standard protocol with HPLC quantification to 
determine the maximum solubility of the drug in the delivery vehicle solution. Drug release is typically 
assessed with permeation studies (196, 199). This method involves separating a donor and receiving 
chamber with a tissue sample layer of cells grown to confluence, and measuring the amount of drug that 
travels from the donor chamber, through the cell layer, into the receiving chamber. However, this method 
of assessing drug release measures the overall diffusion of the drug from the formulation to the site of 
action. However, in this dissertation, the initial release of the drug from the delivery vehicle formulation 
is the property of interest. This the above method (197) was selected to measure the release of drug 
initially out of formulation through a semi-permeable membrane. 
Also in Chapter 4, the QSPRs generated for the rheology, safety, and efficacy properties in the 
proceeding chapters will be incorporated into an optimization problem formulation that will be solved to 
generate novel delivery vehicle molecular structures that possess ideal physical properties and behavior. 
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The successful completion of this design problem serves as a proof of concept that CMD can be 
applied to this pharmaceutical field. This methodology can then be expanded to characterize and predict 
other types of microbicide delivery vehicles, the APIs themselves, and other small molecules and simple 

























Quantitative Structure-Property Relationships for Rheological Properties of Cellulose 
Ether Vaginal Microbicide “Gels” 
2.1 Introduction 
Patient acceptance, along with drug delivery effectiveness, in vaginally-delivered microbicides 
which contain polymer solutions (i.e. “gels”) determines the success of a microbicide formulation. A 
recent clinical trial of CAPRISA 004 (128), a 1% tenofovir gel, resulted in an overall 39% reduction in 
HIV infection compared to the placebo arm. However, individuals with use adherence over 80% had a 
54% reduction in infection, demonstrating the crucial impact patient adherence and acceptability have on 
drug product effectiveness. The subsequent VOICE clinical trial (129), which looked at daily treatment 
with a 1% tenofovir gel or oral tablets, and the FACTS 001 clinical trial (130), which looked at pericoital 
treatment with a 1% tenofovir gel, failed to reduce rates of HIV infection in any treatment arm. The 
studies specifically cited low adherence as the reason for a lack of efficacy. 
Patient acceptability studies (154, 155) have analyzed how patient sensory perceptions of vaginal 
microbicide products could influence patient adherence. In particular, these studies have sought to relate 
these sensory perceptions to physical properties of the microbicide formulation. Patients (154) believe a 
specific volume of the microbicide must be placed within the vagina and this volume must be retained in 
order to form a barrier between the epithelium and infectious agents. If the microbicide changes color or 
consistency or leaks out prematurely, the patient believes it has reduced effectiveness and is less likely to 
use it again. This desired retention and consistency of the microbicide depends upon the rheological 
properties of the formulation (155). To achieve efficacy and acceptability, the microbicide must spread 
such that it coats the vaginal wall, without leaking. It also must be retained for a sufficient amount of time 
to deliver the API to the appropriate site while providing lubrication and serving as a potential barrier to 
infectious agents during intercourse. To achieve the desired degree of spreading, the delivery vehicle must 
exhibit optimal rheological properties that allow it to coat and be retained in the vagina.  A next 
generation microbicide should include a delivery vehicle possessing these optimal properties.  
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This study aims to advance the field of microbicide development by illustrating how quantitative 
correlations relating polymer molecular structure and physical properties can be used to create a 
predictive model. This predictive methodology is demonstrated with a cellulose-based delivery system, 
but could also be expanded to other delivery vehicles. This work is initiated by selecting and 
characterizing a group of representative molecules to serve as the model building set. The structural and 
physical properties of this model building set are also measured and correlated. In later studies, these 
correlations are incorporated into an optimization problem to generate similar, but novel, molecular 
structures with target physical properties. In many pharmaceutical fields, predictive models like the one 
developed in this study have been successfully used in tandem CMD (157) to predict properties such as: 
solubility and permeability (159), controlled release from hydrogels (181), and physiochemical properties 
of cross-linked polymers (180). Similarly, the significance of the predictive model in this study is that it 
will be used, along with a final CMD model, to design improved microbicide delivery vehicles or select 
candidate structures that possess the best spreading behavior. When combined with predictive models for 
other properties (e.g. biocompatibility and drug compatibility), this predictive model will allow for the 
development of a microbicide formulation with target properties that lead to multiple functions (e.g. target 
drug loading, release, spreading behavior, inhibition of C. trachomatis, and minimization of cytotoxicity) 
with improved behavior compared to currently available products.  
Cellulose ethers in aqueous solutions are a possible delivery vehicle and are currently used in 
several over-the-counter vaginal products available in the U.S. market, as well as the “universal placebo” 
used in clinical microbicide trials (200). Cellulose ethers are alkyl modifications of cellulose that vary in 
type of substituent, amount of substitution, and molecular weight. The molecular structure of these 
molecules has a great impact on their physical properties, including their rheological properties. Previous 
rheological characterization of cellulose ethers in the microbicide field (201-205) as well as other drug 
delivery fields (206-208) has examined the effects of concentration, temperature, pH, and dilution on 
physical properties such as viscosity and elasticity. These previous works measured rheology of one or a 
few cellulose ether solutions and fit these data to rheological constitutive models; some of the previous 
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work incorporated these rheology data into coating or squeezing flow models. In particular, Mahalingam 
et. al. (203) used mixture design of experiments theory to relate concentration of mixtures of 
hydroxyethyl cellulose and Carbopol 974P to physical properties and spreading performance. That study 
identified a gel mixture with optimal rheological properties and spreading behavior. These collective 
studies concluded that the physical properties of different cellulose ether solutions responded differently 
to variations in dilution, temperature, and concentration. However, the causes of these differences due to 
effects of molecular structure on rheological behavior of cellulose-based polymer solutions have not been 
addressed, nor have any property-structure correlations been proposed. Additionally, this current study 
improves upon these previous studies by measuring a wide range of cellulose ethers with unique 
structures, many of which have not been evaluated for use as vaginal microbicide delivery vehicles. 
This study addresses this gap by focusing on molecular structure and concentration of a wide 
range of cellulose ether solutions. To rationally design an effective delivery vehicle using these polymers 
requires an understanding of how variations in molecular structure impact rheological properties, 
specifically those properties which determine spreading behavior of the delivery vehicle. The goal of this 
study is to elucidate the impact of molecular weight, concentration, substituent group, and amount of 
substitution on rheological properties for a wide range of cellulose ethers to aid in future delivery system 
design. The outcome will consist of a set of empirical correlations that will predict the rheological 
properties of cellulose ether solutions based on these structural factors and formulation choices. The large 
model building set in this study allows for the development of quantitative correlations, while previous 
rheology studies with more limited data sets could only elucidate general trends. This study’s template of 
data acquisition and analysis will be used in later studies to elucidate how molecular structure impacts 
drug compatibility, and biocompatibility, and will be used to accomplish the final goal of designing the 
molecular structure of a microbicide delivery vehicle. 
2.2 Materials and Methods 
2.2.1 Cellulose Ethers and Rheology 
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Cellulose ethers are widely used in solution as rheology modifiers and to thicken formulations 
(209). They are utilized in a wide variety of industries including construction, oil field chemicals, 
personal care products, food additives, and pharmaceuticals. In the pharmaceutical field cellulose ethers 
are incorporated into drug tablets to create controlled release matrices (210), into saliva substitutes to 
relieve dry mouth (211), in mucoadhesive buccal disks for oral pro-drug delivery (212), or in ophthalmic 
viscosurgical devices to minimize damage in eye surgery (206). Additionally, the use of hydroxyethyl 
cellulose (HEC) in KY Jelly, a commercial vaginal lubricant, has led to the development of a “universal 
placebo” in vaginal microbicide clinical trials (200) based on Natrosol, a proprietary HEC from 
Hercules/Aqualon. 
In order to rationally design an appropriate cellulose ether for use in a microbicide delivery 
vehicle, its specific rheological properties must be identified. This current study emphasizes non-
Newtonian viscosity (described by consistency and shear-thinning index), shear storage modulus, and 
shear loss modulus. Previous studies of thin film spreading indicate that consistency and shear-thinning 
index have an impact on the time the solution takes to spread due to gravity (213, 214) and squeezing 
forces (205, 215), the length it covers, and if fingering patterns develop in the flow that would create 
undesired bare spots in the coverage area (216). The storage and loss moduli (also known as elastic and 
viscous moduli) represent the elastic and viscous effects of the moving fluid and the ratio of these values 
influences how the solution is retained or if it continues to flow and leak (217). These two dynamic 
moduli are measured under oscillatory flow conditions, which are relevant to topical drug delivery 
vehicles exposed to oscillatory shear stresses during application and use. 
A wide range of cellulose ethers were selected to form a model building set and their rheological 
properties were measured over a range of shear rates and oscillatory frequencies. The “universal placebo” 
currently in clinical microbicide trials (200) contains HEC as the rheology modifier. This study focuses 
on the rheology of aqueous solutions of HECs at various molecular weights to create a model building set 
with a range of rheological properties. This range is further increased by the incorporation of the 
additional cellulose ether, sodium carboxymethyl cellulose (CMC). 
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2.2.1.1 Cellulose Ethers 
Natural cellulose is highly crystalline, and the lower chemical potential of crystals due to 
hydrogen-bonding causes the molecules to be insoluble in water (218). To create aqueous cellulose 
solutions this crystalline order must be disrupted by the addition of side chain substitutions that prevent 
tight packing and expose the hydrophilic glucose repeat units to the solvent. In addition, the side chains 
themselves can be hydrophilic. Cellulose ethers are produced by modifying the hydroxyl groups on the 
glucose units in the cellulose chains. Specifically, an alkyl substituent group replaces the hydrogen atom 
on these hydroxyl groups. These substituent groups can include hydroxyethyl, carboxymethyl, methyl, or 
hydroxypropyl substitutions. The molecular structure of the cellulose ethers depends on the molecular 
weight, the type of substituent groups, the degree of substitution (DS), and molar substitution (MS). 
Degree of substitution indicates on average how many of the three hydroxyl groups on each glucose 
repeat unit have substitutions (see Figure 2.1). For hydroxyethyl cellulose, since the additional hydroxyl 
group in the substitution group can receive a substitution, the MS refers to on average how many 
hydroxyethyl groups are present at each substitution site. If the MS is large, this can lead to long side-
group chains branching off of the main cellulose strand (219). 
 
Figure 2.1: Two glucose repeat units in a cellulose chain. The ether modifications are made by replacing 
the hydrogen on a hydroxyl group with a substitution group. 
 
The universal placebo (200) consists of a solution containing 2.7% HEC in water with trace 
amounts of sorbic acid, sodium chloride, and sodium hydroxide to increase biocompatibility with the 
vaginal epithelial cells and native lactobacteria. Viscosity studies conducted in our lab using the universal 
placebo formulation indicated that the presence of salts and preservatives had a negligible impact on the 
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solution viscosity (data not shown). HECs have very little viscosity variation over a pH range of 2 to 12, 
while CMCs have very little viscosity variation over a pH range of 4 to 10 (220). Thus, in this study, the 
cellulose ethers were mixed in water in the absence of buffer, salt, or any preservatives to create polymer 
solutions. 
Several cellulose ethers were tested to vary molecular weight, substituent group, and MS/DS (see 
Table II.I). The average molecular weight of the molecules was obtained from commercial product 
information. The manufacturer-provided molecular weight values are approximate and based on average 
viscosity behavior, reflecting synthesized polymer batches which may have high polydispersity. These 
polydispersity indices may be highly variable since they are unpublished. Additionally, all cellulose 
ethers were tested at several concentrations to create the final model building set. The concentration range 
was based around the concentration of the universal placebo and increased for low viscosity solutions, 
corresponding to the lower molecular weight formulations. This was done to create a model building set 
with rheological properties that were broad, but excluded viscoelastic moduli that were too low, which 
would cause them to immediately leak out of the vagina, or high, which would cause them to fail to 
spread upon insertion. Overall, 29 polymer solutions of cellulose ethers formed the model building set, as 
show in Table II.I. 
Table II.I: 29 Cellulose Ether Polymer Solutionsa 
Name Molecular Weightb MS/DSb Concentration 
Hydroxyethyl Cellulose (HEC, Natrosol 250 HX 
Pharm, Hercules/Aqualon)c Mv=1,000,000 2.5/1.5 2.4%, 2.7%, 3.0% 
Hydroxyethyl Cellulose (HEC, Sigma-Aldrich) 





12%, 14%, 16% 
2.7%, 6%, 7%, 8% 
2.4%, 2.7%, 3.0% 
2.4%, 2.7%, 3.0% 
Carboxymethyl Cellulose (CMC, Blanose 7HF PH, 
Hercules/Aqualon) Mw=700,000 NA/0.7 
2.0%, 2.4%, 2.7%, 
3.0%, 3.3% 
Carboxymethyl Cellulose 
(CMC, Sigma-Aldrich) Mw=250,000 
NA/0.9 
NA/1.2 
2.7%, 6%, 7%, 8% 
2.7%, 6%, 7%, 8% 
aSolutions were generated by varying ether type, molecular weight, MS/DS, and/or concentration. bMolecular weight and MS/DS data were obtained from Sigma-Aldrich and Hercules/Aqualon. 
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cThe hydroxyethyl cellulose used in the “Universal Placebo.” 
 
2.2.1.2 Rheology 
 The shear-thinning viscosity and shear moduli were measured on a rheometer (TA Instruments 
AR2000) at 37°C. The viscosity was measured using a 40 mm 2° cone over a range of shear rates from 
0.01 to 100 1/s. The mean of three replicates were then fit to the following power-law model (221) to find 
power-law parameters: 
=     Equation 2.1 
where μ is the viscosity, m is the consistency,  is the shear rate, and n is the shear-thinning index. Several 
models exist to describe shear-thinning viscosity data. The power-law model captures both the 
consistency and shear-thinning behavior over a range of shear rates, and is used often to describe 
rheology of pharmaceutical formulations, e.g. (222). The power-law model was also selected for it 
applicability for non-cross-linked polymers and for its integration with previous and concurrent fluid 
mechanics studies in our research group (214, 216). Future expansion of this study may include the Ellis 
rheological model, which may better describe the spreading behavior of the cellulose ethers in the model 
building set, especially at the low shear-rate Newtonian plateau (213). 
The shear moduli were measured by performing oscillatory frequency sweeps using a 40 mm 
plate at a constant stress in the linear viscoelastic regime over a range of frequencies from 0.01 Hz to 1 
Hz. This provided frequency-dependent data for the storage modulus, G’, and the loss modulus, G’’. The 
G’ and G” data were represented as the mean of three uniquely loaded samples for each solution. In 
contrast to the power-law behavior for the viscosity data, it was not possible to find a robust constitutive 
equation to capture the frequency-dependent behavior for G’ and G”, due to the wide range of samples. 
For this reason the data analysis focuses on representative G’ and G” values at a specific frequency, while 
example plots show the full range of data. 
2.2.2 Construction of QSPRs 
 These rheology data were then used to create a set of Quantitative Structure-Property 
Relationships (158), or QSPRs. These QSPRs relate the physical properties (consistency, shear-thinning 
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index, storage modulus, and loss modulus) to the molecular topology and concentration of the cellulose 
ethers solutions. The four structure properties used for the correlations were: the average molecular 
weight of the polymer chains, the polymer concentration in solution, and two zeroth-order connectivity 
indices. 
Connectivity indices assign numerical values to the graph of a molecule to quantify its 
topological structure (223). They contain a wealth of information such as the numbers of atoms bonded to 
each non-hydrogen atom, details about the electronic structure of each atom, and larger-scale structural 
features in a few numbers. Connectivity indices have been shown to be highly effective for the prediction 
of physical properties of straight-chain polymers (223). The zeroth-order connectivity indices are group 
contribution descriptors which adequately describe the average repeat unit structure. They are calculated 
as follows: 
 = ∑     Equation 2.2 
 = ∑     Equation 2.3 
Each non-hydrogen atom is defined as a vertex. The  represents the number of bonds to non-hydrogen 
atoms at vertex i. The  represents the sum of the lone pair electrons at the ith vertex plus its number of 
bonds to non-hydrogen atoms. Figure 2.2 shows an example calculation for a simple polymer repeat unit. 
This allows for the calculation of a pair of connectivity indices for each of the unique cellulose ether 
polymers in Table II.I. These results are shown in Table II.II. 
Figure 2.2: Diagram showing example calculation of zero-order connectivity indices for a simple 
polymer repeat unit of poly vinyl fluoride. The vertices include all non-hydrogen atoms.   represents the 
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number of bonds to non-hydrogen atoms at each vertex i, while  represents the number of bonds to 
non-hydrogen atoms plus lone pair electrons at the ith vertex. Adapted from (223). 
 
Table II.II: Calculated Connectivity Indices for Unique Cellulose Ether Solutionsa,b 
Cellulose Ether MS DS      HEC 2.5 1.5 13.35 10.33 
HEC 2.0 1.0 12.29 9.41 
CMC NA .7 10.14 7.14 
CMC NA .9 10.74 7.53 
CMC NA 1.2 11.64 8.11 
a Calculations of connectivity indices were based on MS/DS values for an average glucose repeat unit. 
b The two connectivity indices (   and  ) are defined in Equations 2.2 and 2.3.  
To create QSPRs, the four physical measurements (consistency, shear-thinning index, storage 
modulus, and loss modulus) were each correlated with the four structural properties (two connectivity 
indices, concentration, and molecular weight). The QSPR correlations were generated using R statistical 
software (224). These correlations were evaluated using goodness of fit (r2), which indicates the accuracy 
of the predictive model. Additionally, cross validation was performed to indicate the predictive quality of 
the correlations, represented as q2, and to reduce over-fitting of descriptors in QSPR selection. The 
method selected was leave-one-out cross-validation, which estimates the goodness of fit on independent 
data sets by leaving out one data point, re-correlating the rest of the data, evaluating the new correlation 
using the outlier point, repeating this for each data point, and summing the resulting r2 values to generate 
a q2 value. Linear and nonlinear dependence on the four structural properties, as well as interaction terms 
between the structural properties, were considered when generating QSPRs. The QSPRs with the best 
goodness of fit and cross-validation performance were identified from these possible correlations with the 
three structural descriptors. 
2.3 Results 
In this section, the rheology results and trends are presented.  The effects of several factors are 
isolated:  concentration, molecular weight, substituent type, and MS/DS.   After each of these is presented 
and shown how they are related, the following Discussion section will demonstrate the construction of 
nonlinear and interaction terms in the QSPRs. 
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Representative rheology data for all cellulose ether solutions in the model building set are 
displayed in Table II.III. These data describe the viscosity data using power-law fit parameters and the 
viscoelastic data by representative values taken at the maximum, minimum, and midpoint of the 
frequency measurement range. Rheology data points for some representative polymer solutions from 
Table II.I are shown in Figures 2.3 through 2.9. These figures display viscosity and storage modulus data; 
loss modulus plots are not shown for brevity. These figures do not represent all available data, but allow 
for discussion of molecular structure effects on physical properties in the following sections and 
identification of some trends for insight on improving the correlations. 
Table II.III: Representative Viscosity Dataa,c and Viscoelastic Datab,d for all 29 Cellulose Ether 
Solutions. 
Cellulose Ether Solution m (P*sn-1) n r2 G’ at 0.01 Hz (Pa) G’’ at 0.01 Hz (Pa) 
2.4% HEC MW=1,000,000 212.79 0.5975 0.9804 1.72±0.15 4.98±0.27 
2.7% HEC MW=1,000,000 376.81 0.5494 0.9782 4.18±1.25 9.66±2.14 
3.0% HEC MW=1,000,000 506.58 0.5127 0.9772 5.12±0.34 11.17±0.52 
12% HEC MW=90,000 30.18 0.9468 0.9999 0.0025±0.00083 0.19±0.0059 
14% HEC MW=90,000 73.27 0.9335 0.9993 0.018±0.0019 0.48±0.012 
16% HEC MW=90,000 170.58 0.8771 0.9983 0.13±0.0079 1.57±0.049 
2.7% HEC MW=250,000 2.27 0.9406 0.9997 0.042±0.014 0.58±0.015 
6% HEC MW=250,000 45.14 0.8946 0.9988 0.021±0.0014 0.34±0.014 
7% HEC MW=250,000 91.17 0.8683 0.9979 0.044±0.0078 0.70±0.019 
8% HEC MW=250,000 189.24 0.8260 0.9966 0.14±0.034 1.51±0.18 
2.4% HEC MW=720,000 93.41 0.6658 09883 0.29±0.00067 1.22±0.014 
2.7% HEC MW=720,000 128.27 0.6425 0.9873 0.52±0.068 1.87±0.11 
3.0% HEC MW=720,000 191.72 0.6156 0.9857 0.85±0.0078 2.83±0.027 
2.4% HEC MW=1,300,000 389.81 0.5441 0.9768 3.04±0.080 7.64±0.11 
2.7% HEC MW=1,300,000 473.45 0.5202 0.9757 4.45±0.48 10.04±0.74 
3.0% HEC MW=1,300,000 655.57 0.4937 0.9751 5.49±0.0051 12.03±0.036 
2.0% CMC MW=700,000 118.96 0.5360 0.9820 0.76±0.045 1.33±0.031 
2.4% CMC MW=700,000 395.43 0.3704 0.9597 5.01±0.051 4.74±0.026 
2.7% CMC MW=700,000 533.25 0.3078 0.9571 8.72±0.32 6.41±0.14 
3.0% CMC MW=700,000 914.79 0.2466 0.9679 22.46±1.52 13.07±0.70 
3.3% CMC MW=700,000 1378.32 0.2212 0.9798 40.19±1.46 20.96±0.64 
2.7% CMC 0.9 MW=250,000 8.10 0.9053 0.9996 0.0017±0.0012 0.051±0.0024 
6.0% CMC 0.9 MW=250,000 404.91 0.5686 0.9887 2.30±0.068 3.87±0.040 
7.0% CMC 0.9 MW=250,000 934.87 0.4509 0.9829 5.53±0.0078 8.00±0.040 
8.0% CMC 0.9 MW=250,000 2103.82 0.3316 0.9732 26.90±0.50 22.35±0.62 
2.7% CMC 1.2 MW=250,000 3.80 0.9577 0.9996 0.0018±0.00060 0.023±0.0024 
6.0% CMC 1.2 MW=250,000 59.13 0.9029 0.9983 0.011±0.0014 0.42±0.0082 
7.0% CMC 1.2 MW=250,000 107.79 0.8787 0.9974 0.042±0.00066 0.84±0.0086 
8.0% CMC 1.2 MW=250,000 178.77 0.8522 0.9966 0.083±0.0061 1.42±0.017 
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Cellulose Ether Solution G’ at 0.1 Hz (Pa) G’’ at 0.1 Hz (Pa) G’ at 1 Hz (Pa) G’’ at 1 Hz (Pa) 
2.4% HEC MW=1,000,000 14.63±0.74 24.32±0.98 76.45±7.20 74.80±6.80 
2.7% HEC MW=1,000,000 29.01±6.88 41.63±7.46 126.29±23.44 111.03±16.54 
3.0% HEC MW=1,000,000 32.80±1.59 45.69±167 142.80±5.35 121.77±4.90 
12% HEC MW=90,000 0.10±0.0083 1.77±0.061 1.85±0.086 15.70±0.49 
14% HEC MW=90,000 0.37±0.014 4.09±0.13 6.25±0.21 33.61±1.28 
16% HEC MW=90,000 2.05±0.11 12.43±0.446 26.79±1.13 87.47±2.69 
2.7% HEC MW=250,000 0.64±0.014 5.02±0.050 12.99±018 34.67±0.28 
6% HEC MW=250,000 0.36±0.024 3.05±0.12 6.16±0.30 23.27±0.84 
7% HEC MW=250,000 0.92±0.037 6.05±0.14 13.77±0.54 42.75±1.57 
8% HEC MW=250,000 2.48±0.38 12.14±1.28 30.22±2.17 77.30±3.05 
2.4% HEC MW=720,000 3.24±0.037 7.25±0.082 22.19±0.21 28.83±0.26 
2.7% HEC MW=720,000 5.12±0.32 10.40±0.43 31.92±1.24 38.76±0.98 
3.0% HEC MW=720,000 7.93±0.050 15.01±0.12 47.23±1.08 54.32±1.25 
2.4% HEC MW=1,300,000 22.52±0.36 34.57±0.44 111.93±4.79 100.59±4.24 
2.7% HEC MW=1,300,000 30.26±2.35 42.63±2.36 134.70±7.62 114.13±5.56 
3.0% HEC MW=1,300,000 35.97±1.07 50.64±0.80 168.37±6.10 139.93±5.40 
2.0% CMC MW=700,000 3.74±0.083 6.15±0.088 19.12±0.29 23.29±0.31 
2.4% CMC MW=700,000 15.17±0.23 15.84±0.13 53.36±2.17 48.89±1.98 
2.7% CMC MW=700,000 21.63±0.58 18.29±0.18 63.14±2.16 51.61±1.33 
3.0% CMC MW=700,000 48.87±2.89 32.32±1.25 119.97±6.13 80.73±3.09 
3.3% CMC MW=700,000 84.47±2.98 49.57±1.02 194.13±4.88 118.00±2.59 
2.7% CMC 0.9 MW=250,000 0.041±0.0073 0.48±0.015 0.73±0.037 4.03±0.11 
6.0% CMC 0.9 MW=250,000 10.38±0.050 19.07±0.11 55.82±1.21 86.63±2.15 
7.0% CMC 0.9 MW=250,000 23.09±0.32 35.79±0.45 105.61±6.49 140.27±8.92 
8.0% CMC 0.9 MW=250,000 73.15±3.22 74.27±3.25 245.93±11.59 249.80±12.04 
2.7% CMC 1.2 MW=250,000 0.016±0.012 0.22±0.011 0.16±0.047± 2.07±0.013 
6.0% CMC 1.2 MW=250,000 0.35±0.0078 3.91±0.075 7.91±0.20 31.31±0.78 
7.0% CMC 1.2 MW=250,000 0.92±0.0065 7.58±0.098 17.34±0.46 57.60±1.90 
8.0% CMC 1.2 MW=250,000 1.80±0.035 12.54±0.18 29.33±0.90 84.91±2.70 
a Viscosity measurements are tabulated as the power-law parameters: m (consistency) and n (shear-
thinning index). b Viscoelasticity measurements are tabulated as G’ (shear storage modulus) and G’’ (shear loss modulus) 
at a representative frequency. 
c The power-law parameters were fit to the mean of triplicate data, and the of the fit is shown. d For G’ and G”, the mean ± standard deviation (n=3) is given. 
 
2.3.1 Concentration Effects 
Figures 2.3 through 2.5 and Table II.III illustrate rheological property variation with solution 
concentration. As seen in studies with similar cellulose solutions (206-208), the viscosity, storage 
modulus, and loss modulus increase with increasing polymer concentration for all solutions measured 
while n decreases. The data shown in these figures indicate that this increase in physical properties is not 
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linear with concentration. For example, for the HEC in Figure 2.3, the increase in consistency, apparent 
viscosity, and elastic moduli from a concentration of 2.4% to 2.7% is greater than the increase from 2.7% 
to 3.0%. The nonlinear influence of concentration on viscosity is also observed in Figure 2.4a for a CMC. 
Figures 2.3 and 2.4 show just two examples of nonlinear variation of physical properties with 
concentration, but all cellulose ether solutions in Table II.III had similar trends, which indicates that 
standard linear regression cannot adequately relate viscosity or elasticity to concentration. 
The rheological properties in Figure 2.5 for a low molecular weight HEC indicate that molecular 
weight moderates the concentration effects. Table II.III reveals that each increase in concentration in 
Figure 2.5 more than doubles the resulting rheological properties with an especially large increase in the 
storage modulus, but this requires a 2% increase in solution concentration. To increase the apparent 
viscosity at the lowest shear rate by approximately two times, the low molecular weight HEC requires a 
concentration increase of 2% while the high molecular weight HEC requires an increase of less than 
0.6%. 
Figure 2.3a and 2.3b: Effects of Concentration of HEC (high MW). Example viscosity (2.3a) and 
viscoelasticity (2.3b) data for hydroxyethyl cellulose (HEC) with a molecular weight of 1,000,000. Data 
points indicate median ± max/min for replicates. 
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Figure 2.4a and 2.4b: Effects of Concentration of CMC (higher MW). Example viscosity (2.4a) and 
viscoelasticity (2.4b) data for carboxymethyl cellulose (CMC) with a molecular weight of 700,000. Data 
points indicate median ± max/min for replicates. 
 
Additionally, substituent groups appear to moderate concentration effects. A concentration 
increase of 0.4% raises the viscosity at the lowest shear rate of the high molecular weight CMC by nearly 
an order of magnitude (Figure 2.4b). The same increase for either molecular weight of HEC would 
require a concentration increase of several percent. These differences in physical property variation with 
concentration between difference cellulose ethers with different molecular weights and substituent groups 
are explored in the following sections. 
 
Figure 2.5a and 2.5b: Effects of Concentration of HEC (low MW). Example viscosity (2.5a) and 
viscoelasticity (2.5b) data for hydroxyethyl cellulose with a molecular weight of 90,000. Data points 
indicate median ± max/min for replicates. 
 
2.3.2 Molecular Weight Effects 
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 Figures 2.6 and 2.7 illustrate rheological property variation with molecular weight at constant 
solution concentration. In the previous section, Figures 2.3 through 2.5 indicated that the dependence of 
rheological properties on concentration was also highly dependent upon molecular weight, as expected. 
Furthermore, physical properties do not vary linearly with molecular weight for HECs or CMCs. For 
example, Figure 2.6a shows that the viscosity decrease is magnified as the MW of HEC is decreased. This 
decrease results in the viscosity at the lowest shear rate decreasing by nearly two orders of magnitude. 
The decrease for the CMC in Figure 2.7 is even more pronounced. 
The HEC in Figure 2.6 indicates a high degree of nonlinearity in the variation of physical 
properties with molecular weight. The HEC data, shown in Figures 2.3, 2.5, and 2.6 collectively, indicate 
that the rheological properties have an increasing dependence on concentration as molecular weight 
decreases. In addition, there is a decreasing dependence on molecular weight as the concentration 
increases. Additional comparison of Figures 2.6 and 2.7 indicates that substituent groups also moderate 
molecular weight effects. The variation in properties between a lower and higher molecular weight is 
much greater for the CMC than the HEC. These variations between substituent groups are further 
explored in the next section. 
 
Figure 2.6a and 2.6b: Effects of Molecular Weight of HEC. Example viscosity (2.6a) and viscoelasticity 
(2.6b) data for hydroxyethyl cellulose at a concentration of 2.7% with a DS of 1.5 (the molecular weight 
of 720,000 hydroxyethyl cellulose has a DS of 1.0). Data points indicate median ± max/min for replicates. 
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 Figure 2.7a and 2.7b: Effects of Molecular Weight of CMC. Example viscosity (2.7a) and viscoelasticity 
(2.7b) data for carboxymethyl cellulose at a concentration of 2.7%. Data points indicate median ± 
max/min for replicates. 
 
2.3.3 Substituent Effects 
Figure 2.8 depicts rheological property variation due to changes in the substituent groups of 
cellulose ethers at approximately constant molecular weight. Confirming trends displayed in Figures 2.3 
through 2.7, there are clear differences in physical properties with variation in substituent groups. Figure 
2.8 shows that for the same molecular weight and concentration, the viscosity of a CMC is over an order 
of magnitude higher than the HEC at the lowest shear rates, and the storage modulus is approximately two 
orders of magnitude higher than that of HEC. A similar increase in viscosity and storage modulus can be 
observed when comparing Figure 2.6 (HEC 720,000) and Figure 2.7 (CMC 700,000). 
 Figure 2.8a and 2.8b: Effects of Substituent Group. Example viscosity (2.8a) and viscoelasticity (2.8b) 
data for carboxymethyl cellulose (DS = 0.9) and hydroxyethyl cellulose (DS = 1.0), both with a molecular 
weight of 250,000 at a concentration of 6.0%. Data points indicate median ± max/min for replicates. 
 
2.3.4 MS/DS Effects 
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The MS/DS for a cellulose ether indicates the number of side chain substitutions on average per 
glucose repeat unit. The carboxymethyl groups on CMCs do not have additional hydroxyl groups to 
facilitate longer side chains, so only a DS number is needed to describe this behavior. The hydroxyethyl 
groups on HECs do have an additional hydroxyl group which can further react, forming longer side chain 
substitutions. In a group contribution model, the MS is the important number to describe an HEC since is 
enumerates all the side groups present, not just the substitutions sites as described by the DS. 
Figure 2.9 illustrates that the degree of substitution in addition to the type of substitution for 
CMCs also has a dramatic impact on physical properties. The increase in degree substitution from 0.9 to 
1.2 caused the low shear-rate viscosity of the CMC to decreases by over an order of magnitude and the 
low-frequency storage modulus to decrease by over two orders of magnitude. These data, along with 
Figure 2.8, indicate that both the degree and type of substitution influence physical properties. 
 Figure 2.9a and 2.9b: Effects of DS/MS. Example of viscosity (2.9a) and viscoelasticity (2.9b) data for 
carboxymethyl cellulose DS = 0.9 and DS = 1.2 with a molecular weight of 250,000 at a concentration of 
6.0%. (The DS = 0.9 data are the same data shown in Figure 2.8 for the CMCs.  It is interesting to note 
that the DS = 1.2 CMC data here are similar to the HEC data in Fig 2.8.) Data points indicate median ± 
max/min for replicates. 
 
2.4 Discussion 
In this section, I describe the construction of the quantitative structure-property relationships 
(QSPRs), which are formed from an analysis of the rheological results and trends presented above.  First, 
I discuss the rheological trends and the process for determining nonlinear and interaction terms in the 
QSPRs. Subsequently, I discuss the interpretation and limitations of the QSPRs. 
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2.4.1 Nonlinear and Interaction Terms in QSPRs 
 The preceding rheological results indicate that the physical properties of the cellulose ether 
solutions do not linearly depend on variations in structural properties. Figures 2.3 through 2.9 show that 
rheological properties vary nonlinearly with concentration or molecular weight, and that there are 
interactions between the dependence on concentration, molecular weight, and the degree/type of 
substitution. Thus, we expected that a QSPR formed from only linear correlations with structural 
properties would not perform well. Table II.IV shows the linear QSPR correlations with the best goodness 
of fit. The goodness of fit for the correlation of the shear-thinning index is fairly low (r2 under 80%), and 
the correlations for the other three physical properties are unacceptably poor for the purposes of property 
prediction and molecular optimization. 
Table II.IV: Linearly Regressed QSPRs for the Physical Propertiesa Correlated with the Structural 
Parametersb. 
Correlation r2 c 
m = 2838 + 9.31x10-4 MW + 7545 C – 317.6 0χ + 51.6 0χV 0.3940 
n = -1.255 - 6.23x10-7 MW – 2.493 C + 0.3441 0χ – 0.1977 0χV 0.7875 
G’ = 130.6 + 5.17x10-5 MW + 303.2 C – 18.38 0χ + 7.055 0χV 0.4569 
G’’ = 36.08 + 5.474x10-5 MW + 327.5 C – 0.4751 0χ – 6.361 0χV 0.4863 
a Rheology data from Table III. b Structural parameters are molecular weight, concentration, and the two connectivity indices in Table II. c r2 is goodness of fit. These results reflect that a linear relationship with structural properties is not 
sufficient for predicting physical properties, and thus the nonlinear dependence and interaction of the 
structural properties need to be incorporated into the QSPRs. 
 
The poor performance of the linear QSPRs in Table II.IV indicate that a linear correlation with 
structural properties is insufficient for predicting physical properties of these cellulose ether solutions. 
The linear QSPRs are deficient because they do not capture the nonlinear effects of concentration and 
molecular weight summarized in the preceding sections, and because they do not capture the 
interdependence between the structural properties (concentration and molecular weight). In addition, the 
zeroth-order connectivity indices do not completely capture the impact of the degree of substitution – they 
reflect substituent type, but not the location of nearest neighbors. In other words, treating the structural 
parameters as isolated variables does not adequately reflect how small changes in degree of substitution 
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can have large impacts on the molecular weight and concentration dependence of physical solution 
properties.  
The previous rheological results provide insight into the construction of QSPRs that incorporate 
nonlinear and interaction terms. The next step was to use power relationships to explore single nonlinear 
relationships between each physical measurement and each structural property. For example, Figure 12.10 
shows an example of a CMC consistency (m) varying with concentration with a 4.75 power. Similar 
trends to comparable powers were observed for regressions of shear-thinning, storage modulus, and loss 
modulus (plots not shown for brevity). However, the single nonlinear regressions illustrated the hazards 
of creating single regressions to correlate physical properties across all types of cellulose ethers, since the 
concentration effects on physical properties were more pronounced in CMCs compared to HECs. 
Similarly, the dependence on molecular weight was also not constant between cellulose ethers with 
different substituent groups. These nonlinear single regressions also indicated that consistency had a 
higher dependence upon concentration as compared to molecular weight. 
 Figure 2.10: Example of a power relationship between a physical property (e.g., consistency) and a 
structural property (e.g., concentration).   Consistency variation with concentration for carboxymethyl 
cellulose with a molecular weight of 700,000. These values are the consistency (m) from the same data 
presented in Figure 4a, and demonstrate an example of the nonlinear behavior of each physical parameter 
as a function of each molecular structure parameter (including concentration). 
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The analysis of such single nonlinear trends also highlights the interdependence between 
molecular weight and concentration, confirming existing literature sources (225, 226). The nonlinear 
trends indicate that as molecular weight decreased, the effects of concentration on rheological properties 
became more acute. This result emphasizes that molecular weight and concentration are interdependent, 
inverse properties that cannot be considered as separate variables when developing property-structure 
correlations. Similarly, an analysis of the nonlinear dependence on MS/DS reinforced the importance of 
the type and amount of substitution in determining rheological properties. Taken together, all the 
nonlinear behaviors reinforce the nonlinearity and interdependence of the four structural parameters 
(including concentration) to one another. 
Figure 2.11: Example of two distinct nonlinear trends in a physical property as a function of a single, 
combined structural parameter.   All consistency data plotted against the four structural parameters 
combined as a single combined parameter:  ∗ ∗ ∗    . Two separate trends were evident. The steeper, or higher, trend contains data from the CMCs with a DS of 0.7 and 0.9 while the lower trend 
contains all the HECs and the CMC with a DS of 1.2. 
 
To further explore the interdependence of the structural properties, Figure 2.11 shows the 
consistency data plotted against the structural variables multiplied together to generate a single combined 
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parameter. Figure 2.11 shows a strong nonlinear trend and reveals that the data are divided into two 
clearly demarcated trends. Both follow power regressions for the consistency based on the combined 
structural parameter but one trend has a much steeper slope than the other. The steeper, or higher, trend 
contains data from the CMCs with a DS of 0.7 and 0.9 while the lower trend contains all the HECs and 
the CMC with a DS of 1.2. Interestingly, the two distinct trends are also seen when the storage modulus, 
loss modulus, and shear-thinning index are plotted versus the single structural parameter (plots not shown 
for brevity). However, in the case of the shear-thinning index, the physical variation with the structural 
parameter was linear. The occurrence of the two distinct trends reflects how the zeroth-order connectivity 
indices do no fully capture the type and degree of substitution. 
In summary, the preceding analysis suggests how the collective data can be grouped in a 
meaningful way when forming nonlinear QSPRs, and suggests the use of two separate sets of QSPRs. 
The shape of the plots indicates the final form of the QSPRs. For consistency, storage modulus, and loss 
modulus, the plots indicate power regression as the best functional form, while for shear-thinning index 
the best functional form was linear.  
The final QSPRs, based on nonlinear and interactive terms, for the model building set are shown 
in Tables II.V and II.VI below. They were formed by separating the data into two sets, modeling all the 
physical properties except shear-thinning index using a power regression, and combining structural 
parameters into interaction terms. The power regression QSPRs for each physical property were generated 
by considering all possible combinations of single, double, triple, and quadruple structural parameters and 
selecting the correlation with the best r2 values and q2 values. The QSPR fits improved dramatically from 
the linear case in Table IV and all correlations have r2 values well over 90%. The q2 values are all over 
80% and, excluding the shear-thinning values, are close to the r2 values. The q2 values were formed using 
leave-one-out cross-validation, and since the q2 values are comparable to r2 values, we can conclude the 
correlations are both accurate and useful for prediction. 
This final predictive model is composed entirely of empirical relations between molecular 
structure and rheological properties. The model eschews mechanistic impute and does not consider the 
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causes of the observed behavior. However, the high r2 and q2 values for all the correlations indicates they 
are accurate for describing the observed behavior and predictive of rheological properties for other 
cellulose ether solutions. This methodology provides a framework for creating future predictive property 
models for compounds where information of mechanistic behavior is lacking. 
Table II.V: Final QSPRs for Subset of Model Building Set Containing all HECs and the CMC with a DS 
of 1.2. 
Correlation r2 q2 
m = -367.1 + 4.355x10-7(MW*C)2+52.37 0χ – 32.22 0χV 0.94 0.93 
n = 0.9291 -3.862x10-7 MW - 0.2903 C + 0.03714 0χ - 0.04311 0χV 0.93 0.89 
G’ = 6.2952x10-26(MW*C*0χ)4.7471 0.96 0.95 
G’’ = 1.3687x10-16(MW*C*0χ)3.1231 0.92 0.90 
 Table II.VI: Final QSPRs for Subset of Model Building Set Containing CMCs with a DS of 0.7 and 0.9. 
Correlation r2 q2 
m = 1.7239x10-22(MW*C*0χ)4.6596 0.96 0.95 
n = 1.583 – 1.338x10-6 MW – 1.154 C 0.94 0.81 
G’ = 4.2682x10-34(MW*C*0χ)6.5881 0.99 0.99 
G’’ = 3.2139x10-21(MW*C*0χ)4.1515 0.95 0.95 
 
2.4.2 Interpretation of QSPRs 
The final form of the correlations in Tables V and VI reveal interesting trends about how the 
structural parameters impact the physical properties and their relative importance. As previously stated, 
all correlations are modeled using power regression except for the shear-thinning index since this property 
was accurately described by a linear fit with the structural parameters as independent variables. Also, the 
consistency correlation for the data subset in Table II.V was modeled using a quadratic model since in 
this instance this improved upon the power fit. The power fits also indicate that consistency and loss 
modulus vary with the structural properties to a similar extent while the storage modulus has a steeper 
dependence on the interaction term in both sets of correlations. This behavior suggests that as the values 
of the structural properties increase, the elastic portion of the fluid increases to a greater extent compared 
to the viscous portion. Generally, as the molecular weights, concentrations, and degrees of substitution of 
the compounds increase, the fluid becomes increasingly elastic. As the combined structural parameter 
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increases, the ratio of the viscous portion of the fluid to the elastic portion shifts to favor the elastic 
portion. 
When comparing the two tables, the connectivity indices are much more important in the QSPRs 
in Table II.V compared to Table II.VI. This is because Table II.V fits a larger range of data with more 
diverse structures while Table II.VI is purely CMCs with little variation in DS. In fact, only one 
connectivity index could be used to fit the data in Table II.VI because, for one type of cellulose ethers 
(either all HEC or all CMC), the connectivity indices are interrelated and no longer independent variables. 
Somewhat similarly, only one connectivity index was used in the QSPRs in Table II.V for storage and 
loss modulus. This was because the addition of the second index had little impact on the r2 value and the 
concentration and molecular weight had much greater impacts on the overall accuracy of the fit. 
The dominance of molecular weight and concentration on the physical properties can be seen in 
the correlations in Table II.VI. The shear-thinning index depends solely on these properties and the 
connectivity index in the other three correlations had a much smaller impact on accurate fit than the other 
two structural parameters. This grouping of correlations indicates that the type of cellulose ether and side 
chain structure is much more important when determining which set of correlations to use and has a lesser 
impact on the correlations themselves. 
2.4.3 Limitations of QSPRs 
 The high accuracy and performance of the two QSPR sets allows these correlations to be useful 
for describing the physical properties of cellulose ethers with known structures and allows for 
optimization and design of cellulose ethers for specific applications. The samples in this study revealed 
one trend for all cellulose ethers with a DS above or equal to 1.0 and another trend for all cellulose ethers 
with a DS less than or equal to 0.9. Further research is needed to determine where the exact transition 
between the two trends occurs and if there is a value for the DS that acts as a threshold. 
Further studies may explore techniques to quantify the effects of buffer concentration within the 
QSPRs, as well as the effect of the presence of an API. The current model building set incorporates 
cellulose ethers in aqueous solution with no buffers, preservatives, pH modifiers, or anti-HIV drugs. 
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However, final formulation of a microbicide delivery vehicle with the active agent may require buffers or 
other additives to ensure proper drug performance and reduce irritation with the contacting epithelial 
surfaces (200). Correlations may need to be modified to account for rheological property variations 
caused by such additives. This correction becomes complicated, however, if the effect of buffer 
concentration depends on substituent type. Published rheology data on similar CMC and HEC solutions 
suggest this is the case (206-208). For example, Andrews et. al. (206) conducted experiments with 
solutions using PBS at pH 7.2 instead of pure water at 20°C. The rheology results for the HECs in those 
studies (206, 207) are much higher than those in this study and the results for the CMC (206-208) are 
much lower than those seen in this study. The reduced temperature of those HEC experiments partially 
explains the increase in HEC properties. However, the increase may also be due to the presence of the 
PBS. This buffer may also be responsible for the drastic decrease in CMC properties (206-208) when 
compared to the pure water solution in our study. These differences in behavior may be attributable to the 
charged nature of the carboxymethyl substituent groups whereas all other cellulose ethers are nonionic. 
Such divergent responses to changing buffer concentration between the two types of cellulose ethers is a 
challenge for the development of rheological property-molecular structure correlations that can correct for 
buffer strength. This behavior may even necessitate separate corrected correlations for charged and 
uncharged cellulose ethers. 
The rheological effect conferred by the API seems to be negligible in comparison to this buffer 
effect. Preliminary testing (199) of the tenofovir gel used in the CAPRISA 004 looked at the rheology of 
the final microbicide formulation as well as the universal placebo. That study showed very similar 
rheology for the two formulations, indicating the API has a small rheological impact. This is likely due to 
the fact that the large size of the cellulose ether polymers dwarves the size of most APIs and thus 
dominates the rheological behavior of the final microbicide formulation. 
2.5 Conclusion 
 This study demonstrates that the rheological properties of cellulose ethers exhibit complex 
dependencies on molecular weight, concentration, and substituent group that cannot be adequately 
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described by linear regressions. In order to rationally design microbicide delivery vehicles of cellulose 
formulations, the patterns in rheological properties were analyzed and quantified to produce improved 
correlations and models. The new correlations emphasized the nonlinear dependence of rheological 
properties on molecular weight and concentration. The correlations showed the importance of the identity 
of the substituent group and type of cellulose ether over the amount of substitution of the functional 
groups. The amount of substitution did influence the overall form of the predictive model by clearly 
demarcating two sets of correlations with different trends, allowing for the generation of accurate and 
validated QSPRs. Future studies should consider cellulose ethers with a greater ranges of DS values to 
locate the exact threshold between 0.9 and 1.0 that separates the two QSPR sets. 
 The current set of correlations form a predictive model that can be used to select the appropriate 
cellulose ether product possessing optimal rheological properties for a variety of industrial and medical 
uses. This predictive model is used in the final study to select a cellulose ether with more ideal spreading 
behavior those in current products, such as the universal placebo and clinical trial formulations. Patient 
acceptability studies and mathematical models of spreading indicate the ideal rheological properties that 
correspond with effective microbicide spreading and user acceptance. The correlations in this study 
provide the exact molecular structure and concentration of a cellulose ether solution for use as that ideal 
delivery vehicle. A novel delivery vehicle with optimal properties is designed based solely on knowledge 
of the molecular structure and solution concentration. The template outlined above is utilized in the next 
two studies to generate additional correlations relating molecular structure of this polymer data set to 
biocompatibility and drug compatibility. The final study incorporates these diverse property correlations 
into a molecular design problem that identifies an optimal polymer structure that promotes ideal 







Quantitative Structure-Property Relationships for Inhibition of Chlamydia trachomatis and 
Biocompatibility of Cellulose Ether Vaginal Microbicide “Gels” 
3.1 Introduction 
To be both safe and effective, anti-HIV vaginal microbicides must possess a number of ideal 
physical, chemical, and biological properties. A microbicide must be retained in the vagina sufficiently 
long enough to deliver the active drug to its proper site of action so as to inactivate or otherwise block or 
halt HIV infection. Microbicides that offer short-term protection must be safe for repeated and extensive 
use. The formulations should not harm, disrupt, irritate, or promote an inflammatory response on the 
vaginal epithelium (190). These criteria apply to both the active drug that prevents infection and the 
delivery vehicle that carries the drug to the site of action.  
The healthy cervicovaginal surface provides an efficient barrier against infections and diseases (227). 
Intact epithelial cells of the female genital tract prevent microbe diffusion and penetration into the body 
while cervical mucus traps and washes microbes out of the genital tract. This intact vaginal epithelium 
surface resists HIV infection when challenged. This is because epithelial cells lining the vagina and cervix 
do not possess target receptors susceptible to HIV binding, and thus HIV cannot enter and infect these 
cells. For a microbicide formulation to be safe for repeated and extended topical use it must preserve this 
environment. Additionally, vaginal microbicide formulations used to prevent HIV transmission must lack 
pro-inflammatory activities. Mucosal inflammation recruits activated CD4-positive cells, such as helper 
T-cells, macrophages, and dendritic cells, which serve as HIV host cells. This recruitment and activation 
facilitates viral replication and enhances HIV-1 penetration through epithelial tissues (228).  
Several cytokines facilitate the activation of these recruitment pathways and thus their upregulation 
indicates the presence of inflammation. The presence of some of these pro-inflammatory cytokines 
indicates mucosal surface toxicity and associated inflammation (182). Of these, the cytokine interleukin-8 
(IL-8) is produced by a variety of cells, including vaginal epithelial cells, and recruits neutrophil 
granulocytes, CD4+ T-cells, and macrophages (229). Some cytokines, such as IL-1α, IL-1β, IL-6, and IL-
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8, stimulate HIV-1 replication in infected cells. IL-1α or IL-1β works synergistically with IL-6 to promote 
viral expression and replication in infected promonocyte cells (230). IL-8 promotes viral replication in 
both macrophages and T lymphocytes (231). Additionally, studies (232) of HIV-exposed seronegative 
commercial sex workers have indicated that those individuals with innate HIV immunity display lower 
levels of pro-inflammatory cytokines (IL)-1α, IL-6, and IL-8 compared to HIV negative controls. For 
these reasons up-regulation of these particular cytokines should be avoided when designing a novel 
microbicide formulation to prevent HIV infection. The present study measured increased production of 
IL-6 and IL-8 to access in vitro HIV recruitment associated inflammation. These two cytokines promote 
HIV infection by recruiting different host cells and thus represent different inflammation pathways. 
While minimizing inflammation and recruitment of HIV-vulnerable immune cells, the vaginal 
epithelium must be preserved as a barrier to HIV penetration. Major causes of epithelial disruptions are 
STIs. Vaginal infections, particularly bacterial infections caused by Chlamydia trachomatis, cause vaginal 
lesions that are associated with higher rates of HIV infection when a patient is subsequently challenged by 
the virus (233). An active drug specifically designed to prevent HIV infection may not prevent other 
concurrent STIs. A delivery vehicle that non-specifically prevents such infections would further promote 
the body’s innate defenses and aid overall microbicide efficacy. 
There is a need for novel delivery vehicles that possess optimal biocompatibility and inhibition 
physical properties in next generation microbicides. The final study in Chapter 4 utilizes CMD as a 
methodology to achieve this desired optimization that considers these several different target properties at 
once for a range of candidate molecules. CMD can consider multiple physical properties with conflicting 
targets to produce many possible molecules quickly, which in turn accelerates the process of drug 
discovery. 
The present study looks at the cytotoxicity, pro-inflammatory cytokine production, and C. 
trachomatis inhibition conferred by a set of compounds to determine differences in biocompatibility and 
inhibitory ability based on molecular structure. This is accomplished by measuring biological 
compatibility and inhibition of a model building set of compounds and creating correlations relating the 
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measured properties to structural data. These relationships are incorporated into an optimization problem 
in the final study to generate novel delivery vehicles with optimal physical properties. 
3.2 Materials and Methods 
3.2.1 Materials 
3.2.1.1 Model Building Set: Cellulose Ethers 
To conduct the experiments that generate the QSPR model for the optimization problem, a model 
building set of current delivery vehicles is required. The model building set in this study includes the 
eight cellulose ethers from the first study. The present model building set is expanded by adding two 
methyl celluloses (MCs) and five hydroxypropyl methyl celluloses (HPMCs). This creates a final model 
building set of 15 cellulose ethers possessing various side chain substitutions, degree of substitution, 
molar substitution, and molecular weight. They are shown in Table III.I below. 
Cellulose ether based delivery vehicles have undergone little experimental evaluation. The HEC 
in the Universal Placebo has been extensively characterized (200), but biocompatibility data for similar 
cellulose ethers is lacking. When additional cellulose ethers are considered for evaluation, such as a MC, 
publications fail to report the type of MC and do not include the DS, the molecular weight, or product 
identification (234). Further, the evaluation of this MC focused on rheological properties and drug 
compatibility and neglected safety. Thus, much of the experimental data available in the literature on the 
relevant properties of cellulose ethers cannot be used in this current study because the corresponding 
molecular structure data necessary for correlations is unavailable. 
Table III.I: 15 cellulose ethers evaluated for cytotoxic effects against vaginal cells. The average 
molecular weight, molar substitution, degree of substitution, product information, and label key are 
provided. 
Label Compound MW MS/DS Source 
Nat Hydroxyethyl Cellulose 1,000,000 2.5/1.5 Natrosol 250 HX Pharm 
Hercules/Aqualon 
HEC 1 Hydroxyethyl Cellulose 1,300,000 2.5/1.5 Sigma-Aldrich 
HEC 2 Hydroxyethyl Cellulose 90,000 2.5/1.5 Sigma-Aldrich 
HEC 3 Hydroxyethyl Cellulose 250,000 2.0/1.0 Sigma-Aldrich 
HEC 4 Hydroxyethyl Cellulose 720,000 2.5/1.5 Sigma-Aldrich 
CMC 4 Carboxymethyl Cellulose, sodium salt 250,000 -/0.9 Sigma-Aldrich 




Carboxymethyl Cellulose, sodium salt 700,000 -/0.7 Cellulose Gum 7HF 
Hercules/Aqualon 
HPMC 7 Hydroxypropyl Methyl Cellulose 10,000 0.2-0.3/1.8-2.0 Sigma-Aldrich 
HPMC 8 Hydroxypropyl Methyl Cellulose 86,000 0.2-0.3/1.8-2.0 Sigma-Aldrich 
HPMC E Hydroxypropyl Methyl Cellulose 86,000 0.23/1.9 Methocel E 
Dow Chemical 
HPMC F Hydroxypropyl Methyl Cellulose 86,000 0.13/1.8 Methocel F 
Dow Chemical 
HPMC K Hydroxypropyl Methyl Cellulose 86,000 0.21/1.4 Methocel K 
Dow Chemical 
MC 6 Methylcellulose 40,000 -/1.6-1.9 Sigma-Aldrich 
MC A Methylcellulose 86,000 -/1.8 Methocel A 
Dow Chemical 
 
3.2.1.2 Experimental Reagents and Equipment 
The cytotoxic and inflammatory effects of 15 cellulose ethers were evaluated in vitro using a 
human immortalized vaginal (VK2/E6E7) epithelial cell line (235),  generously provided by our colleague 
Dr. Miezan Ezoulin in Dr. BBC Youan’s laboratory at UMKC. These cells were grown in keratinocyte 
serum-free medium (KSFM) (Life Technologies, Inc.) supplemented with 0.1 ng/ml human recombinant 
epidermal growth factor (EGF), 0.05 mg/ml bovine pituitary extract, and 44.1 mg/L calcium chloride 
(235). Cytotoxicity was assessed by adding cells to 96 well plates and, after a period of incubation 
described below, alamarBlue® (Life Technologies, Inc.) was added and absorbance at 570 and 600 nm 
was read using a spectrophotometer (PowerWave HT Microplate Spectrophotometer). 
Cytokine concentration was determined using Human IL-6 and IL-8 ELISA Kits (BD OptEIATM, 
BD Biosciences) and a spectrophotometer reading absorbance at 450 nm, with a correction at 570 nm. 
Synthetic macrophage-activating lipopeptide-2 (MALP-2) (Enzo Life Sciences) at 50 nM was used as a 
pro-inflammatory control. 
The inhibitory effects were evaluated using C. trachomatis lymphogranuloma venereum (LGV) 
serovar L2/434/Bu elementary bodes (EBs) purified from infected mouse fibroblast (L929)  cells (236), 
generously provided by our colleague Dr. Scott Hefty. The fibroblast cell line (L929) was grown in RPMI 
1640 culture medium (Mediatech, Inc.) supplemented with 5% fetal bovine serum (FBS) (Thermo Fisher 
Scientific) and 10 µg/mL gentamycin (MP Biomedicals) (237). 
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Information about the 15 cellulose ethers is presented in Table III.I above. The HEC known as 
Natrosol and the CMC known as Cellulose Gum 7HF were provided by Hercules/Aqualon. The MC 
known as Methocel A and the HPMCs known as Methocel E, F, and K were provided by Dow Chemical. 
All others were purchased from Sigma-Aldrich. 
3.2.2 Methods 
3.2.2.1 Cytotoxicity Assay 
For the cytotoxicity assessment, VK2/E6E7 cells were added to 96 well plates at 75% of 
confluence (approximately 3x104 cells per well) and given approximately 24 hours to adhere (235). At 
this point the media was removed and replaced with media containing either 0.25% of cellulose ether, or 
media containing no cellulose ether which served as the negative control. A concentration of 0.25% was 
chosen as this was determined to be the maximum concentration at which the solution viscosity would not 
negatively impact cell viability. The plates were incubated with the test compounds for 24 hours. After 
this time the test solutions were removed and fresh media was added containing 10% alamarBlue®. After 
an additional incubation period of 6-7 hours the absorbance was read on a spectrophotometer at 570 and 
600 nm, adapted from (182). 
Cytotoxicity was calculated as the inverse of viability of a sample compared to the control after 
24 hours in VK2/E6E7 cells. All tests were performed in triplicate and the averages of those tests are 
reported, along with the standard deviation. A statistical analysis consisting of t-tests, which compare 
each cellulose ether to the negative control, and a one-way ANOVA, which compared the cellulose ethers 
to each other, was conducted using Windows Excel and p values <0.05 were considered significant. 
3.2.2.2 Pro-inflammatory Soluble Cytokine Assays 
For the inflammation assessment, VK2/E6E7 cells were added to 96 well plates at 75% of 
confluence (approximately 3x104 cells per well) and given approximately 24 hours to adhere. At this 
point the media was removed and replaced with media containing 0.25% of cellulose ether and the plates 
were incubated for 24 hours. After this time the supernatants containing soluble mediators were collected. 
Concentrations of IL-6 and IL-8 were measured using ELISA Kits and a spectrophotometer reading 
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absorbance at 450 nm and correcting at 570 nm, adapted from (183). Concentrations were compared to a 
negative control of media with no compound and a positive control of MALP-2 (50 nM) (238). As was 
done for the cytotoxicity data, all tests were performed in triplicate and the averages of those tests are 
reported, along with the standard deviation. A statistical analysis consisting of t-tests, which compare 
each cellulose ether and MALP-2 to the negative control, and a one-way ANOVA, which compared the 
cellulose ethers to each other, was conducted using Windows Excel and p values <0.05 were considered 
significant. 
3.2.2.3 Chlamydia trachomatis Inhibition Assay 
For the inhibition assessment, infectious forms of C. trachomatis (L2/434/Bu) cells, known as 
EBs, were incubated with cellulose ether compounds at room temperature for 1 hour at a concentration of 
0.25%. This mixture was added for a 2 hour pre-infection at room temperature to a monolayer of L929 
mouse fibroblast cells plated the previous day. At this time the supernatant was removed, fresh media was 
added, and the L929 cells were incubated for an additional 24 hours. At the end of this time the cells were 
fixed with methanol, stained, and analyzed. The level of infection inhibition was determined relative to a 
buffer control containing no compounds and Polymyxin B serving as a positive inhibition control, from 
(184). All tests were performed in triplicate and the averages of those tests are reported, along with the 
standard deviation. The experiments were graciously performed by collaborator Dr. Ichie Osaka in Dr. 
Scott Hefty’s laboratory as per the author’s instructions. 
3.2.2.4 QSPR Generation 
The biocompatibility and inhibition data were incorporated into a set of Quantitative Structure-
Property Relationships, or QSPRs. These QSPRs relate physical properties to molecular topology of the 
cellulose ethers. In the present study the relevant physical properties are percent cytotoxicity, IL-6 and IL-
8 concentration, and percent inhibition of C. trachomatis. The molecular topology of the cellulose 
compounds is represented by molecular structural descriptors. These descriptors include the average 
molecular weight and two zeroth-order connectivity indices used and described in the previous study. The 
connectivity indices were calculated using the same equations and method as described in the previous 
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study of rheological properties. Those equations generate a pair of connectivity indices for each cellulose 
ether polymer with a unique MS/DS. The results for the expanded model building set are shown in Table 
III.II below. 
Table II: Calculated Connectivity Indices for Unique Cellulose Ether Solutionsa,b 
Cellulose Ether MS DS      HEC 2.5 1.5 13.35 10.33 
HEC 2.0 1.0 12.29 9.41 
CMC NA .7 10.14 7.14 
CMC NA .9 10.74 7.53 
CMC NA 1.2 11.64 8.11 
HPMC 0.2-0.3 1.8-2.0 10.14 8.27 
HPMC 0.23 1.9 10.08 8.21 
HPMC 0.13 1.8 9.71 7.85 
HPMC 0.21 1.4 9.32 7.68 
MC NA 1.6-1.9 9.29 7.45 
MC NA 1.8 9.32 7.50 
a Calculations of connectivity indices were based on MS/DS values for an average glucose repeat unit. 
b The two connectivity indices (   and  ) are defined in Equations 2.2 and 2.3.  
To generate the QSPRs two biological measurements (cytotoxicity and inhibition of C. trachomatis) 
were correlated with up to three structural properties (average molecular weight and the two connectivity 
indices above). Pro-inflammatory cytokine production, measured as the production of IL-6 and IL-8, were 
omitted from the QSPR model for reasons described below. The final correlations were produced using R 
statistical software (224), and evaluated for accuracy using r2 and predictive quality using q2 as described 
in the previous rheological study. Linear and nonlinear dependence on the three structural properties, as 
well as interaction terms between the structural properties, were considered when generating QSPRs. The 
QSPRs with the best goodness of fit and cross-validation performance were identified from these possible 
correlations with the three structural descriptors. 
3.3 Results 
In this section, the biocompatibility results and trends are presented. The effects of molecular weight, 
substituent type, and MS/DS are presented, and the following Discussion section will illustrate the 
construction of a QSPR model using these trends. 
3.3.1 VK2/E6E7 Cytotoxicity Assay Reveals Structure Dependent Response 
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VK2/E6E7 cells were incubated with cellulose ether compounds for 24 hours before their 
viability was assessed using an alamarBlue® assay. Several replicates of this experiment were carried out 
and Figure 3.1 below shows a representative data set. Cellulose ether derivatives from commercial 
sources, such as the ones listed in Table III.I, are considered “generally recognized as safe” (GRAS) 
chemicals by the FDA. However, as Figure 3.1 shows, variable viability was observed across the model 
building set and several compounds produced moderate cytotoxic effects in excess of 20%. These effects 
were statistically significant (p < 0.05) compared to the negative control for all compounds except HPMC 
E and MC 6. 
 
Figure 3.1: Cytotoxic response induced by cellulose ethers. Cytotoxicity was calculated as the inverse of 
viability of a sample compared to the control after 24 hours in vaginal (VK2/E6E7) cell lines. Bars 
represent means of triplicate experiments and error bars represent standard deviation. All compounds had 
p values < 0.05 compared to the negative control, with the exception of HPMC E and MC 6. ANOVA 
results are described in the text. 
While most of the compounds produced a significant cytotoxic effect compared to the control 



















































molecular structure. In particular, the type of side chain substitution appears to be the dominant molecular 
effect causing differential toxicity. The CMCs consistently have the highest cytotoxicity. HECs have an 
intermediate, though still pronounced cytotoxicity. Lastly, the MCs and HPMCs have more variable 
cytotoxic levels, though collectively they are lower still than the HECs. This indicates that the charge 
character or polarity of the polymer molecules might have an impact on the epithelial cells. CMCs are 
ionized salts, the side chains of HECs are non-charged polar groups, the side chains of HPMCs are non-
charged slightly polar groups, though to a far lesser degree than HECs, and the side chains of MCs are 
non-charged non-polar groups. Figure 3.1 suggests that as a cellulose ether becomes less charged and less 
polar, moving from CMC to HEC to HPMC or MC, cytotoxicity decreases. 
In addition to the t-tests performed to evaluate the statistical significance of each cellulose ether 
compared to the control, a one-way ANOVA was performed to assess the statistical significance of the 15 
cellulose ethers compared to each other.  The results were somewhat less pronounced than the t-tests 
comparing the compounds to the control. Even so, several cellulose ethers displayed statistical 
significance compared to each other with p < 0.05. MC 6 was significantly lower than all the CMCs, all 
the HECs except Nat, and HPMC F. HPMC E was significantly lower than all the CMCs and all the 
HECs except Nat and HEC 3. HPMC 8 was significantly lower than all the CMCs and HECs 1 and 2.  
Finally, Nat, MC A, and HPMCs 7, F, and K were significantly lower than CMCs 4 and 5. These results 
consistently indicate that a difference of approximately 25% indicates that the cellulose ethers are 
significantly different from each other. 
The results of replicate assays were variable such that the numerical value of the cytotoxic effect 
produced by each compound changed. Compounds with low cytotoxicity, such as the HPMCs and MCs, 
in some replicates might exhibit no or even negative cytotoxicity in other replicates. Compounds with 
moderate cytotoxic effects, such as the HECs, might exhibit low cytotoxicity in other replicates that did 
not prove statistical significance. However, the overall trends were preserved between replicates. CMCs 
always exhibited the highest cytotoxicity to statistical significance. HPMCs and MCs exhibited the lowest 
cytotoxic levels and were often not cytotoxic or exhibited very marginal effects.  HECs exhibited 
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moderate cytotoxic effects between the two other types of cellulose ethers. Some replicates indicated a 
pronounced moderate level of cytotoxicity above 20% and some replicates were lower than this threshold, 
suggesting these compounds produce marginal toxic effects. These marginal effects might be acceptable 
for many drug formulations but may cause adverse effects in a topical formulation designed for repeated 
and prolonged use. Thus it would be desirable to minimize these effects in a final formulation. 
3.3.2 Cytokine Assays Reveal Negligible Pro-inflammatory Response 
 
Figure 3.2: IL-6 production induced by cellulose ethers. Pro-inflammatory response induced by cellulose 
ethers indicated by production of IL-6 after 24 h exposure in vaginal (VK2/E6E7) cell line. Triplicate 
replication with standard deviation error bars. Bars represent means. 
Initially the cellulose ether compounds were not expected to produce a significant pro-
inflammatory response. This assumption was made for similar reasons to the initial assumption about 
cytotoxic effects. The wide variety of pharmaceutical applications cellulose ethers are currently used for 
would indicate an absence of harm. The slight cytotoxic effects produced by some of the tested 
compounds in the previous section revised this estimation. For this reason the pro-inflammatory effects of 
the cellulose ethers were evaluated by measuring production of IL-6 and IL-8 using ELISA kits. Several 





























































and IL-8 production, respectively. There were no experimentally consistent, statistically significant 
increases in production of IL-6 or IL-8 compared to the negative control of media caused by any of the 15 
cellulose ethers. 
The IL-6 data displayed in the representative replicate in Figure 3.2 does exhibit a slight, 
statistically significant increase in production compared to the negative control for HECs 2 and 4. 
However, such trends are absent from other data replications where the negative control is slightly higher. 
These marginal, inconsistent changes to IL-6 production caused by the cellulose ethers indicate these 
compounds have little impact on IL-6 upregulation. These marginal fluctuations become especially trivial 
when compared to the dramatic, almost 10-fold increase in IL-6 conferred by the positive control, MALP-
2, which stimulates cytokine production in VK2 cells. The lack of consistent statistical significance 
between experimental replications precludes the construction of a QSPR relating IL-6 production to 
cellulose ether molecular structure. This subsequently prevents the use of IL-6 production as a physical 
property in the final design optimization problem. 
 Figure 3.3: IL-8 production induced by cellulose ethers. Pro-inflammatory response induced by cellulose 
ethers indicated by production of IL-8 after 24 h exposure in vaginal (VK2/E6E7) cell line. Triplicate 
replication with standard deviation error bars. Bars represent means. 
The IL-8 data displayed in Figure 3.3 does not display any statistically significant increase in 


























































even more clearly than in the case for the IL-6 data since the IL-8 production of the negative control for 
the replicate shown is either equal to or greater than the compounds. For the IL-8 data MALP-2 produced 
an approximately 5-fold increase in production compared to the negative control, further reinforcing the 
lack of upregulation conferred by the compounds. Just as with the IL-6 data, the lack of statistically 
significant upregulation of IL-8 compared to the negative control along with the lack of variability 
between the different cellulose ether compounds precludes the construction of a QSPR relating IL-8 
production to molecular structure. Fortunately for clinical use, both data sets indicate cellulose ethers do 
not produce unfavorable cytokine responses. Unfortunately for this study these data cannot be used in a 
final optimization problem. 
3.3.3 C. trachomatis Assay Reveals Variable Inhibition Response 
L929 cells were incubated with a mixture of EBs and each of the 15 cellulose ethers for two hours 
and then for another 24 hours post-exposure to allow the C. trachomatis infection to grow before being 
stained with methanol and enumerated. These results are shown in Figure 3.4 below. The purpose of this 
study was to see if any cellulose ether compounds provided a non-specific barrier to C. trachomatis 
infection and, if so, did the degree of inhibition have any relation to molecular structure. Figure 3.4 
indicates that several of the compounds exhibited moderate inhibition of C. trachomatis in excess of 30% 
and a few had over 50% inhibition. Further, the large variability between the 15 compounds indicates 
differences in degree of inhibition due to molecular structure. 
The data in Figure 3.4 reveal trends when considered in groupings due to substituent type. Nat 
and HEC 1 had the highest degree of inhibition (over 50%) while HEC 2 has the lowest inhibition. 
Interestingly, Nat and HEC 1 are the HECs with the highest molecular weight while HEC 2 has the lowest 
molecular. Considering the HECs in isolation, there is a very strong dependence of degree of inhibition on 
molecular weight. From highest to lowest molecular weight, the HECs are ordered as HEC 1 > Nat > 
HEC 4 > HEC 3 > HEC 2. This is very similar to the order of highest to lowest inhibition for the HECs: 
Nat > HEC 1 > HEC 4 > HEC 3 > HEC2. 
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 Figure 3.4: Inhibition of C. trachomatis induced by cellulose ethers. Inhibition was calculated as the 
inverse of infection compared to control after 2 hour exposure. Bars represent means of triplicate 
experiments and error bars represent standard deviation. 
The trends for the data for the HPMCs and MCs are similar to those for the HECs, though less 
pronounced. HPMCs 8, E, F, and K have the same molecular weight and similar MS/DS structure. Thus 
they would be expected to exhibit similar physical properties. This is mostly true for the inhibition data, 
although HPMC E is somewhat higher than the others, even though its structure is almost the same as 
HPMC 8. Fortunately, the molecular weight trend for the HECs does continue for these data. HPMC 7 
has a lower molecular weight than the other HPMCs and also has a slightly lower degree of inhibition. 
Similarly, MC 6 has a much lower molecular weight than MC A and a slightly lower degree of inhibition 
as well. The consistency of this trend of inhibition correlating with average molecular weight suggests a 
possible QSPR to describe these data, as discussed in the next section. 
One interesting trend that is not readily apparent from Figure 3.4 is that HPMCs and MCs appear 
to have a higher inhibitory ability compared to the HECs and the CMCs. At first look at Figure 3.4, the 
high molecular weight HECs and CMCs had the highest degree of inhibition while the HPMCs and MCs 
were in the middle of the present data set. However, all the HPMCs and MCs tested had much lower 



















































weight HPMCs and MCs (HPMCs 8, E, F, K and MC A) had an average molecular weight of 86,000. 
This is comparable to HEC 2, which had a molecular weight of 90,000. At around the same molecular 
weight some of the HPMCs and MCs had double the inhibition conferred by an HEC. Since the rest of the 
data indicates an increase in inhibition with an increase in molecular weight, this suggests that HPMCs 
and MCs with molecular weights comparable to Nat and HEC 1 would have even higher degrees of 
inhibition than displayed in Figure 3.4. These trends relating inhibition to molecular structure, particularly 
molecular weight and substituent group type suggest that this data set will be useful for the generation of 
a QSPR predictive model that can be incorporated into a later optimization problem to design novel 
compounds with non-specific inhibitory effects. 
3.4 Discussion 
The following section will expand upon the trends discussed in the above results section in order to 
construct quantitative structure-property relationships (QSPRs). These will form a predictive model that 
will be incorporated into a design problem formulation in future work. The preceding results sections 
began to identify trends in these data relating biological properties to molecular structure. Unfortunately 
the limited variation and negligible difference from the negative control in the pro-inflammatory results, 
represented in this study as IL-6 and IL-8 production, prevent any further analysis of these data or 
incorporation into any sort of predictive model. Fortunately, both the cytotoxicity and C. trachomatis 
inhibition data displayed more statistically significant variations between compounds and their negative 
controls. Further, there seemed to be variation in observed data correlating with variation in molecular 
structure. This allows for the possible construction of a predictive model incorporating these two 
properties. However, further analysis will be described in the following sections before constructing such 
a model. 
3.4.1 Exploration of Trends and Generation of Cytotoxicity QSPR 
The QSPR analysis begins by considering the cytotoxicity data in Figure 3.1. These data seem to 
indicate a logical progress correlating cytotoxicity to molecular structure. In particular substituent group 
effects appear to be particularly strong. As described above, the CMCs have the highest cytotoxicity, the 
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HECs are intermediate, and the MCs/HPMCs have the lowest cytotoxicity. This overall progression 
seems somewhat linear, so a linear correlation using all 15 compound cytotoxicity points was attempted. 
The molecular descriptors included average molecular weight and two connectivity indices to indicate 
substituent type as well as MS/DS. The resulting correlating was fair, but not particularly accurate, with 
an r2 value of 0.79. To improve upon this figure, further analysis was performed. 
Since the cytotoxicity trend seemed to depend upon substituent group, each type of cellulose 
ether was isolated for further analysis. Examining the trends by substituent type revealed that effects of 
substituent type dwarfed all other molecular descriptors. The HECs have similar MS/DS values but 
widely varying molecular weight. However, there was no clear relation between the molecular weight of 
these compounds and cytotoxicity. Nat and HEC 1 are the highest molecular weight HECs, while HEC 2 
and HEC 3 have the lowest molecular weights. Yet HEC 1 and HEC 2 have similar cytotoxicity values, at 
the high end of the HEC data, and Nat and HEC 3 have similar, lower values. This mismatch between 
cytotoxicity and molecular weight continues for the other types of compounds. The CMCs indicate that 
increasing molecular weight might decrease cytotoxicity while the MCs indicate the opposite. CMC 7HF 
has a higher molecular weight than CMCs 4 and 5, which have slightly higher cytotoxicity. Conversely, 
MC A has a higher molecular weight than MC 6 and a higher cytotoxicity. The HPMCs are also erratic 
with respect to molecular weight. HPMC 8, E, F, and K all have the same molecular weight, but HPMC 8 
and E have very low cytotoxicity and HPMC F and K are about twice as high. HPMC 7 has a much lower 
molecular weight than the other four yet is comparable in cytotoxicity to HPMC F and K. For these 
reasons cytotoxicity cannot be correlated with molecular weight in any meaningful way. This lack of 
relationship hinders the accuracy of a QSPR using the three previously mentioned molecular descriptors 
and all 15 cytotoxicity data points. 
To overcome this limitation, data was averaged to achieve the final QSPR form for the 
cytotoxicity data. Since cytotoxicity depended heavily on substituent group but not on molecular weight 
or MS/DS variations, each type of cellulose ether was grouped together in the final QSPR. A zero-order 
connectivity index, 0χ, was used to identity the type of cellulose ether. For the HECs the five cytotoxicity 
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values were averaged as were the five corresponding 0χ values. This was repeated for the CMCs, HPMCs, 
and MCs, resulting in four cytotoxicity values and four indices. A further correction value was required to 
generate the final QSPR. The CMCs have intermediate 0χ values but the highest cytotoxicity values. 
Several scalar corrections were evaluated and a scalar of 1.5 multiplied by the average 0χ value of the 
CMCs resulted in a correlation with the best r2 value. This correction was necessary because the CMCs 
are actually sodium salts and the ionized sodium in their structures is not taken into account in the 
calculation of the connectivity indices. It appears in the case of cytotoxicity this attribute of the molecular 
structure is important. 
The final correlation is shown in Table III.III below and the predictive model is illustrated in 
Figure 3.5. The QSPR fit is improved dramatically by grouping substituent type together, raising the r2 
from 0.79 to essentially 1 (0.997). The q2 value is also extremely high (0.99), indicating that the QSPR is 
highly useful for predicting average 0χ and thus for identifying the proper substituent group. This QSPR 
can be incorporated into a future optimization problem formulation. 
Table III.III: Final QSPR for Cytotoxicity Data. 
Correlation r2 q2 



















Figure 3.5: QSPR fitting cytotoxicity data to substituent type. 0χ from least to greatest is MC, HPMC, 
HEC, and CMC. 
3.4.2 Exploration of Trends and Generation of C. trachomatis Inhibition QSPR 
Creating a QSPR using the C. trachomatis inhibition data from Figure 3.4 requires more thorough 
analysis than of the cytotoxicity data in the previous section. The larger degree of variability in the data 
compared to the cytotoxicity data makes cursory identification of trends difficult. For instance, contrary to 
the cytotoxicity data, the inhibition data shows large variability within the same substituent type. Further, 
within substituent type there does appear to be correlation between degree of inhibition and molecular 
weight. The inhibition conferred by the HECs is highest for high molecular weight HECs and lowest for 
low molecular weight HECs. This pattern is repeated for the HPMCs, the MCs, and some (but not all) of 
the CMCs. After this trend was identified, a linear correlation relating C. trachomatis inhibition to 
molecular weight and the two connectivity indices was attempted. The resulting QSPR had an r2 of 0.65, 
much too low for use in a predictive model. Other correlation forms, such as power, exponential, or 
logarithmic did not provide a substantial improvement to the accuracy of the QSPR. 
Since a single QSPR did not seem to fit the entire data set well, the data was analyzed separately by 
substituent group to elucidate any further trends and to determine if a subset of the data could be 
incorporated into a more limited, but more accurate QSPR. In particular the HEC data had a strong 
dependence upon molecular weight. A linear correlation relating just these five inhibition data points to 
molecular weight had a fair r2 value (0.88). However, a power-law correlation relating HEC inhibition to 
molecular weight had a very high r2 value (0.97). This correlation was highly accurate and could be used 
in a predictive model. Further, the power was raised to a decimal less than one, contrary to the positive 
powers displayed in the rheology QSPR model in the previous paper. This indicates that for the HEC and 
CMC substituent groups at a fixed concentration there is an upper limit of inhibition after which further 
molecular weight increases have little impact. 
The other data in the other three substituent groups was analyzed to see if it would fit in this 
correlation. This analysis identified CMCs 4 and 7HF, but not CMC 5, as having behavior remarkably 
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similar to the HECs and thus this data was used to generate a QSPR relating molecular weight to C. 
trachomatis inhibition. Incorporating either connectivity index into this equation in any relation actually 
lowered the r2 value and thus these descriptors were omitted. This QSPR is shown as A in Table III.IV 
and Figure 3.6 below. Once again, the very high r2 and q2 values indicate that this QSPR is both accurate 
and predictive and thus useful in a predictive model for a future optimization problem. 
The remaining data was then analyzed to determine if all the data could be incorporated into a 
predictive model with a separate QSPR. This remaining data consisted of all the HPMCs, all the MCs, 
and the CMC with DS = 1.2. Luckily, this remaining data did seem to correlate with molecular structure. 
In particular this data exhibited a very similar dependence upon molecular weight as the HEC and CMC 
subset, with degree of inhibition rising with increased molecular weight. The form of the correlation was 
also similar to the QSPR for the HECs and CMCs as a linear correlation was fair, but a power-law 
dependence raised to a decimal power was better. However, even with a smaller subset of data the 
accuracy was lower than useful (r2 = 0.71). This low accuracy was due to the HPMCs. These compounds 
had very similar MS/DS values and fairly similar degrees of inhibition. In addition, four of these 
compounds, HPMC 8, E, F, and K, had the same average molecular weight. Thus there was little variation 
in molecular structure and degree of inhibition to differential these data. When correlated with HPMC 7, 
MC 6, MC A, and CMC 5, the other four HPMCs grouped around one point on the graph. With half the 
data at one point, this skewed the results of the correlation, putting extra emphasis on this point and 
lowering the overall accuracy (calculated as r2) of the correlation. For this reason the HPMCs with the 
same molecular weight were averaged as was done for the cytotoxicity data. The two connectivity indices 
and degree of inhibition were averaged for these four points to give a single, average HPMC with 
molecular weight of 86,000.This resulted in a data set consisting of five points: CMC 5, MC 6, MC A, 
HPMC 7, and an average HPMC with a molecular weight of 86,000. 
The final correlation for this half of the data is shown as B in Table III.IV and Figure 3.7 below. The 
analysis described in the previous paragraphs resulted in a QSPR with dramatically improved accuracy 
and predictive power, raising r2 to 0.95 and q2 to 0.94, very near the values for the QSPR for the HEC and 
60  
other CMC data. The power of the correlation is lower, indicating that the upper limit of inhibition 
conferred by HPMCs and MCs is generally lower than that of the HECs and CMCs. Similar to that 
previous QSPR, this QSPR depends heavily on molecular weight. In addition, this subset of the data did 
display some variation with the connectivity indices. In particular, as the indices increased the inhibition 
tended to decrease. Thus this QSPR depends upon the combined parameter of molecular weight divided 
by connectivity indices multiplied together. 
Table III.IV: Final QSPRs for Inhibition of C. trachomatis Data. QSPR A contains all the HEC data as 
well as CMCs with DS = 0.7 and 0.9. QSPR B contains all the MC and HPMC data as well as CMC with 
DS = 1.2. The HPMC with Molecular Weight = 86,000 were averaged. 
Correlation r2 q2 
A: inh = 0.001169(MW)0.4489 0.97 0.95 
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Figure 3.7: QSPR fitting MCs, HPMCs, and CMC (DS = 1.2) to molecular weight divided by 
multiple of connectivity indices. HPMCs with molecular weight = 86,000 are averaged. 
 
3.4.3 Interpretation of QSPR Model 
 The preceding three QSPRs form a model to predict cytotoxicity and inhibition of C. trachomatis 
infection based on molecular structure descriptors. This predictive model is intended as a purely empirical 
model devoid of mechanistic impute. These models are not intended to indicate the causes of the observed 
behavior. Such a methodology allows for the creation of predictive property models for compounds where 
structural data exists but information on mechanistic behavior is lacking. The high r2 and q2 for all QSPRs 
in the current predictive model indicate that they both accurately predict the current observed behavior 
and are predictive of the behavior other cellulose ether compounds. 
 In addition to providing a valid empirical model, the current predictive model does give some 
indication of possible biological mechanisms for the observed behavior. The inhibition of C. trachomatis 
is highly correlated with molecular weight. As the molecular weight increases, so does the degree of 
inhibition. Previous work has shown that molecular weight is highly correlated with viscosity. Thus the 
inhibition might be due to viscosity effects. The increasingly viscous cellulose ether solutions may non-
specifically inhibit the diffusion of the EBs and in that manner prevent infection. A low cellulose ether 
















were Newtonian with a viscosity approaching that of water. However, some small variations might 
remain and influence inhibition behavior. 
 Conversely, cytotoxicity has no dependence upon molecular weight, but does correlate highly 
with substituent type. This indicates that increasing viscosity is not impacting the health of the cells, but 
the type of cellulose ether does. This QSPR indicates that cytotoxicity increases from MCs to HPMCs to 
HECs to CMCs. Interestingly, this trend is from least to most polar substituent. MCs have non-polar 
methyl groups surround the cellulose core. HPMCs have mostly methyl groups with a few polar 
hydroxypropyl groups facing the solution. HECs have all polar hydroxyethyl groups covering the 
exterior. Finally, CMCs create a charged solution of ionized sodium and carboxymethyl groups. This 
trend indicates that the negatively charged and highly polar cellulose ether compounds irritate or 
otherwise harm the cells while the non-polar MCs are less hazardous. This trend is consistent with 
expectations since ionic compounds create hyperosmolar solutions, which are thought to increase toxic 
effects on cells (239). This might also explain the failure of cellulose sulfate as a vaginal microbicide 
since cellulose sulfate is ionic in solution and might produce marginal cytotoxic effects (113). These 
competing phenomena allow for a robust optimization problem formulation in which different molecular 
characteristics can be prioritized to create a novel, ideal delivery vehicle with minimal cytotoxicity and 
maximal inhibition of C. trachomatis. 
 There are limitations to the present study that will influence the final optimization study. The 
averaging done to generate some of the QSPRs will limit the accuracy of the predictive model. In 
particular, the cytotoxicity QSPR can be used to predict which substituent type has a certain range of 
cytotoxicity, but not necessarily the exact cytotoxicity for each unique MS/DS for each predicted 
compound. Since the HPMC data had to be averaged for the inhibition QSPR, this correlation predicts 
molecular weight and that a compound should be a HPMC, but not necessarily the MS/DS of that HPMC. 
Finally, the experimental error was not reflected in the final predictive model, which only considered the 
correlation error. Optimization problems using similar methodologies, such as Roughton et al. (177), 
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propagated such error through the final correlations to indicate a range of predicted structures that are 
statistically similar. 
3.5 Conclusions 
This study demonstrates that some biological properties of cellulose ethers exhibit dependency upon 
molecular structure. These dependencies correlate with different aspects of molecular structure, such as 
substituent group and molecular weight, and exhibit different correlation forms, such as linear and power 
regressions. Not all of the data was successfully correlated with the connectivity index method for 
quantifying molecular structure, but enough data did generate accurate and predictive QSPRs useful for a 
predictive model of biocompatibility and inhibition. Future studies should incorporate cellulose ether 
compounds with a greater range of MS/DS values to explore if these values have any impact on 
cytotoxicity and to resolve more clearly the demarcation between the two inhibition QSPRs. 
This set of QSPRs form an accurate predictive model that can be used to select other cellulose ether 
compounds with optimal cytotoxicity for a variety of topical medical applications and optimal inhibition 
of C. trachomatis for vaginal and anal formulations. This predictive model can be used to select a 
cellulose ether compound with lower cytotoxicity and higher or lower inhibition of C. trachomatis than in 
current products. Designing for lower inhibition will allow for the production of a true universal placebo 
formulation that does not confer unevaluated protection against C. trachomatis, which will non-
specifically prevent HIV infection. It will also prevent the production of a universal placebo formulation 
with slight cytotoxicity which could produce unintended harm in patients and thus skew the results of 
clinical trials. Additionally, this model can be used to produce a microbicide formulation with increased 
non-specific inhibition of C. trachomatis infection which in turn could boost inhibition of HIV conferred 
by the microbicide.  
The correlations detailed above can produce novel cellulose ether molecular structure for these 
disparate uses. This allows for the design of an ideal placebo and ideal microbicide using only knowledge 
of molecular structure. This methodology was successfully completed in a previous study of rheology and 
in this current study of biocompatibility. This predictive model will be is expanded in the next study to 
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generate additional correlations relating molecular structure of this model building set to drug 
compatibility, in particular drug loading and release. The final study incorporates all these diverse 
property correlations, including the biocompatibility and inhibition correlations detailed above, the 
rheological correlations in the previous study, and the drug compatibility correlations created in the next 
study, into a molecular design problem. This design problem formulation is solved to identify optimal 






















Quantitative Structure-Property Relationships for Drug Solubility and Release and Computational 
Molecular Design of Cellulose Ether Vaginal Microbicide “Gels” 
4.1 Introduction 
To provide efficacy against HIV, vaginal microbicides must possess a number of optimal physical, 
chemical, and biological properties. The microbicide must be retained at the site of action sufficiently 
long enough to deliver the API at the proper dosage to block, halt, or inactivate HIV. The delivery vehicle 
must solubilize a sufficient concentration of the API and then release the proper dose to the proper site in 
the body depending on the API’s method of action. 
First generation APIs, including surfactants, detergents, and vaginal defense enhancers, tended to 
non-specifically inhibit HIV infection by disrupting the viral envelope, capsid, or lipid membrane (23). 
This class of microbicides has been largely abandoned after a clinical trial of nonoxynol-9 displayed a 
50% increase in HIV infection in the heavy-use treatment group compared to the placebo group (87). The 
next class, polyanions, non-specifically blocks HIV infection by binding to the viral envelope. This class 
too has also fallen out of favor after the largely unexplained failures of large scale clinical trials such as 
PRO 2000 (104) and cellulose sulfate (112). The newest class of microbicides consists of antiretroviral 
(ARV) agents. ARVs may prevent HIV infection by preventing viral entry into host cells, preventing viral 
DNA integration into host DNA, or preventing virion assembly and maturation. A subclass of ARVs is 
reverse transcriptase inhibitors (RTIs). RTIs inhibit virial replication by preventing reverse transcription 
of viral RNA into DNA. This class of drugs is especially promising for microbicide development because 
it includes tenofovir. A clinical trial of CAPRISA 004 (128), a 1% tenofovir gel, reduced HIV 39% 
overall in the treatment arm compared to the placebo, and 54% in individuals with high adherence. For 
this reason tenofovir was chosen as a model API for the current study. 
The specific mechanism of action of tenofovir requires a delivery vehicle with optimal solubility and 
release behavior. Drug solubility limits the size of the dose that can be delivered while release limits the 
dose that reaches the target cells and tissues. These, in turn, limit the overall efficacy of the API. Low 
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aqueous drug solubility presents a major obstacle to formulation design since the drug must be delivered 
through aqueous biological fluids, such as human vaginal fluid. Even hydrophilic drugs, such as tenofovir 
may exhibit different degrees of aqueous solubility depending upon the hydrophilic and ionic behavior of 
the formulation. Conversely, high solubility can be a hindrance to release. Drugs that are highly soluble in 
formulation may resist diffusing out of that formulation if they are less soluble in the release medium. In 
the case of tenofovir, it is imperative that the microbicide release the API out of formulation so it can 
reach the target cells and enter their cytoplasm where it can have activity against the HIV reverse 
transcriptase enzyme. This class of API must be highly soluble in the microbicide formulation and easily 
released to be effective against HIV infection. A high concentration gradient is required to release a 
substantial amount of tenofovir to not only reach the target cells but penetrate within them. The proper 
delivery vehicle formulation is necessary to achieve this optimal action. 
The present study aims to improve microbicide development by providing a framework to develop 
next generation delivery systems with improved properties. This study looks at the solubility of tenofovir 
in and release of tenofovir from a set of formulation compounds to determine differences in drug 
compatibility based on the molecular structure of formulation components. There is a need for novel 
delivery vehicles that possess optimal release profiles as the next generation of microbicides is generated 
with APIs that have ever more specific activity against HIV. A computational framework is desired to 
create these novel DDSs with a range of optimal properties, including drug compatibility, 
biocompatibility and inhibition, and rheology. Computational molecular design (CMD) provides one such 
computation framework. 
CMD (157) is an optimization methodology that generates products with optimal behavior by relating 
that behavior empirically to physical or chemical properties. In turn, these properties are related 
empirically to molecular structure. Novel products are proposed by incorporating these empirical relations 
into an optimization problem formulation and then solving the problem to generate structures that 
correspond to ideal properties and behavior. This methodology is achieved by the following steps. First, a 
set of compounds, known as a model building set, with known molecular structures are selected. The 
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relevant physical or chemical properties of these compounds are then measured. At the same time 
structural descriptors, which numerically describe the molecular structure, are calculated for the 
compounds. These measured data and calculated structural descriptors are then incorporated into QSPRs. 
These QSPRs are integrated into an optimization problem formulation along with a number of structural 
feasibility constraints to ensure chemically possible molecules are generated. This problem is solved to 
generate several novel molecular structures that possess the target physical properties that correspond to 
the desired behavior. CMD is an advantageous methodology because multiple properties and behaviors 
with conflicting optimal targets can be considered within one problem. This problem can be solved 
quickly multiple times to produce many candidate molecules and thus accelerate the timeline of discovery 
by minimizing the need for high-throughput screening. This final study aims to demonstrate the feasibility 
of such a methodology when applied to vaginal microbicide delivery. 
This study demonstrates the completion of a CMD problem to generate candidate structures for ideal 
novel vaginal microbicide delivery vehicles. The present study first measures tenofovir solubility and 
release in a model building set of compounds to determine how molecular structure of a delivery vehicle 
impacts API activity. These data are then correlated with molecular descriptors to create a predictive 
model. This predictive model, along with the rheological, biocompatibility, and inhibition predictive 
models from previous studies, is incorporated into an optimization problem formulation. This 
optimization problem is then solved to generate several candidate novel delivery vehicle structures with 
optimal drug compatibility with tenofovir, optimal rheological properties, and optimal biocapability. 
4.2 Materials and Methods  
4.2.1 Materials 
4.2.1.1 Model Building Set: Cellulose Ethers 
To conduct the experiments that generate the QSPR model for the optimization problem, a model 
building set of current delivery vehicles is required. This current study used the same 15 cellulose ethers 
used in the biocompatibility and inhibitions studies and displayed in Table III.I. 
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 As mentioned in the previous two chapters, cellulose ethers have undergone little experimental 
evaluation. The release of tenofovir from the HEC used in the CAPRISA 004 formulation (199) has been 
evaluated as well as permeation of HIV through the same HEC and a MC (234). However, data on drug 
solubility and drug release are lacking for the wider range of cellulose ethers evaluated in this present 
study. Further, when excipients are evaluated for their impact on drug solubility and release, other types 
of compounds are considered and cellulose ethers are largely ignored (196). Thus, the experimental data 
necessary for the completion of this present study is absent from literature for the current model building 
set of cellulose ethers. 
4.2.1.2 Experimental Reagents and Equipment 
 Model drug tenofovir was graciously provided by Gilead Sciences, Inc. Acetonitrile was 
purchased from Fisher Scientific. Triethylamine and phosphoric acid (85%) were purchased from Sigma-
Aldrich. All water used in the study was Milli Q water purified in a Millipore water purification system 
(Millipore Corporation). The HEC known as Natrosol and the CMC known as Cellulose Gum 7HF were 
generously provided by Hercules/Aqualon. The MC known as Methocel A and the HPMCs E, F, and K 
were generously provided by Dow Chemical. All other cellulose ethers were purchased from Sigma-
Aldrich. 
 Both the solubility and release studies were performed in a thermostatically controlled, benchtop 
CO2 incubator with a built in shaker (New BrunswickTM S41i, Eppendorf).  The release study was 
performed using Spectra/Por cellulose ester membrane dialysis bags (Spectra/Por Float-A-Lyzer G2, 
MWCO 3.5-5 kDa) from Spectrum Laboratories, Inc. The concentration of tenofovir in both studies was 
measured using an HPLC system (Shimadzu Corporation) consisting of an LC-20AB solvent delivery 
system, a DGU-20A3R degassing unit, a CBM-20A system controller, a CTO-20AV column oven, and a 
SPD-20A UV-VIS detector. A KromasilTM C18 column (150 x 4.6 mm, 5 µm) was used for the separation 




The solubility, method adapted from (196), of tenofovir in cellulose ether solutions was found by 
adding an excess of tenofovir powder (over 15 mg) to an aqueous sample of cellulose ether solution (1 
mL). This shaker incubation method was selected as it was performed in several studies, including 
preclinical evaluation of CAPRISA 004 (199). All 15 sample solutions contained 0.675% of cellulose 
ether. Initially solubility testing was attempted at a concentration of 2.7%, modeled on the universal 
placebo concentration. However, at this concentration several solutions were too viscous to allow 
substantial diffusion of tenofovir powder and thus artificially lowered the overall solubility. For this 
reason the concentration of cellulose ether was diluted by a factor of four. These solutions were incubated 
for 24 h (37 °C and 200 rpm) to allow the sample to reach equilibrium. After this time the samples were 
centrifuged (21,000 g, 2 min) to remove any undissolved tenofovir powder. The samples were then 
diluted by a factor of 100 and the concentration of tenofovir was found using the HPLC system described 
below. Triplicate HPLC readings for each sample were measured. 
4.2.2.2 Release 
 The release, method adapted from (197), of tenofovir from cellulose ether solutions was found by 
creating 1 mL solutions of all 15 sample compounds containing 0.675% cellulose ether and 1% tenofovir 
to mirror the solubility study. This method was specifically chosen to isolate the differences in initial 
release from solutions caused by different cellulose ethers. A solution containing 1% tenofovir was 
selected as this was the concentration in the CAPRISA 004 study (199). 1 mL samples of these cellulose 
ether and tenofovir solutions were placed inside sealed membrane dialysis bags. These dialysis bags were 
then submerged in 20 mL of release medium (Milli Q water). The samples were incubated for 6 h at 37 
°C and agitated at 60 rpm to allow the tenofovir to release from the solution, through the semi-permeable 
membrane, and into the release media. After this time the dialysis bags containing the cellulose ether 
solutions were removed from the release media. The release media were vortexed thoroughly to 
homogenize the concentration of tenofovir, and the released concentration was found using the HPLC 
system described below. Triplicate HPLC readings for each sample were measured. 
4.2.2.3 HPLC Calibration 
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 Concentrations of tenofovir in solution were measured using reverse phase HPLC with UV 
detection, method adapted from (240). The injection volume was maintained at 10 µL and all sample 
measurements were performed in triplicate. The mobile phase was water (pH 5.1) and acetonitrile (35:65 
v/v) at a flow rate of 1 mL/min. The aqueous phase, water (pH 5.1), was prepared by adding 1 mL of 
trimethylamine to 1000 mL of water and adjusting the final pH using phosphoric acid (85%). 
Trimethylamine and phosphoric acid were added to the water to minimize peak tailing. Tenofovir was 
detected by UV absorbance measurement at 259 nm at ambient conditions (25 °C). Ten solutions 
containing different levels of tenofovir concentrations were selected to construct the calibration curve. 
The calibration curve was linear over the concentration range of 100 µg/mL to 2 µg/mL (Figure 4.1 
below).  
 
Figure 4.1: Calibration curve for calculation of concentration of tenofovir in solution using HPLC 
method. Each point represents the mean of triplicate measurements. 
4.2.2.4 QSPR Generation 
The solubility and release data were incorporated into a set of QSPRs (158). These QSPRs relate 
physical properties to the molecular topology of the cellulose ethers. In the present study the relevant 
physical properties are solubility concentration of tenofovir and mass of tenofovir released. The molecular 
topology of the cellulose compounds is represented by molecular structural descriptors. These descriptors 
include the average molecular weight and two zeroth-order connectivity indices described in the previous 

















two studies. The final correlations were produced using R statistical software (224), and evaluated for 
accuracy using r2 and predictive quality using q2 as described in Chapter 2. Linear and nonlinear 
dependence on the three structural properties, as well as interaction terms between the structural 
properties, were considered when generating QSPRs. The QSPRs with the best goodness of fit and cross-
validation performance were identified from these possible correlations with the three structural 
descriptors. 
4.2.2.5 Optimization Problem Formulation and Solution 
 The above described QSPRs were integrated along with QSPRs from previous rheology and 
biocompatibility studies into a predictive model. This predictive model was incorporated with the 
structural descriptors previously described into an optimization problem formulation. The current problem 
takes the form of a mixed-integer nonlinear program (MINLP) (241). This form arises because the 
selection structural side groups require integer decision variables, and some of the predictive QSPRs take 
nonlinear forms. The objective function of the problem formulation seeks to minimize the differences 
between the ideal target property values and the property values predicted by the QSPRs, as shown in 
Equation 4.1 below. This objective function depends upon the QSPR model as well as several structural 
feasibility constraints. In the current problem these constraints include a limiting molecular weight range, 
a limiting concentration range, and a limitation on the number of side chain substitutions to no more than 
three per glucose unit (except for HEC molecules, which can have longer side chain lengths). 
min = ∑ −    Equation 4.1 
where z is the objective function, Pipredicted is the property predicted by the QSPR, Pitarget is the ideal target 
property, and Piscale is a scalar to ensure that properties with very different values (e.g. consistency and 
shear-thinning) are scaled to the same values so one property does not dominate the optimization solution. 
The above problem was solved using the deterministic solver DICOPT in the optimization 
software GAMS (242). This methodology has been used to solve CMD problems in the past (243, 244). 
Since the problem form is MINLP, there are many locally optimal solutions that are not necessarily the 
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global optimum. Solution of the optimization problem will result in one of these local optima. This means 
the most ideal structure will not necessarily be generated. However, the problem can be solved multiple 
times to generate many locally optimal solutions. This behavior is advantageous, however, because not all 
feasibility constraints are included in the problem formulation. Some, such as synthesis feasibility, may 
disqualify solution structures. The generation of multiple molecular structures helps ensure that an 
experimentally feasible molecule will be designed. 
4.3 Results 
 In this section, the drug solubility and drug release results and trends are presented. The effects of 
molecular weight, substituent type, and MS/DS are presented. The section concludes with a presentation 
of the QSPRs generated from the correlation of these data with molecular structure. 
4.3.1 Solubility 
The solubility of tenofovir in all 15 cellulose ether solutions is shown in Figure 4.2 below. 
Further, a one-way ANOVA was performed to assess statistical differences between the cellulose ethers, 
with p < 0.05 considered significant. These data do indicate some differences in tenofovir solubility in 
aqueous solution due to cellulose ether molecular structure. The HECs have fairly constant solubility 
(approximately 2.7 mg/mL). The CMCs have markedly increased solubility (approximately 3.5 to 4.2 
mg/mL) compared to the HECs. This indicates that charged CMC salts facilitate solubility of the 
hydrophilic tenofovir over polar, uncharged HECs. Further, the solubility increase proffered by the CMCs 
does seem to depend upon substitution effects since the solubility of tenofovir increases as the DS 
increases from 0.7 to 0.9 to 1.2. Both the HECs and CMCs do indicate a slight dependence upon 
molecular weight as there is a general trend among both substituent types that as molecular weight 
increases, solubility decreases. 
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Figure 4.2: Solubility of tenofovir in 0.675% cellulose ether solutions. Bars represent means of triplicate 
measurements and error bars represent standard deviations. 
 
The molecular structure effects are less clear for the MCs and HPMCs. The MCs have similar 
solubility compared to the HECs and exhibit just a slight decrease as the molecular weight increases from 
40,000 to 86,000. Conversely, the HPMCs display a decrease in solubility (approximately 1.9 to 2.6 
mg/mL) compared to the other cellulose ethers. These data are fairly consistent except for HPMC 8, 
which has a much higher solubility than the other HPMCs, and is comparable to the MCs and HECs. This 
is unexplained since HPMC 8 has a molecular structure identical to HPMC 7, though at a higher 
molecular weight, and a molecular structure very similar to HPMC E, which has the same molecular 
weight. In general, the cellulose ethers do reveal some differences in tenofovir solubility due to molecular 
structure. This difference appears to be primarily due to substituent type. The HPMCs on average have 
the lowest solubility, the MCs and HECs have similar, intermediate solubility, and the CMCs have the 




















































The results of the ANOVA reinforce these differences and trends. The CMCs had solubility that 
was significantly higher than all other compounds, and CMCs 4 and 5 were significantly higher than 
CMC 7HF. All the HECs and both MCs were significantly higher than HPMCs 7, E, F, and K (although 
not HPMC 8). Additionally, high solubility HECs 2 and 3 were significantly higher than low solubility 
HECs 1 and 4. 
4.3.2 Release 
 The release of tenofovir from all 15 cellulose ether solutions is shown in Figure 4.3 below. 
Further, a one-way ANOVA was performed to assess statistical differences between the cellulose ethers, 
with p < 0.05 considered significant. These data do indicated some differences in amount of tenofovir 
released based on molecular structure, though the trends are quite different from those observed for the 
solubility. Conversely to the solubility data, which tended to decrease with molecular weight with the 
exception of the HPMCs, the release data does not appear to depend upon molecular weight. The HECs 
and MCs indicate a general trend of decreasing release with increasing molecular weight, while the CMCs 
and HPMCs have the opposite trend. There is no compelling reason for why this might be so, since in 
previous studies the HECs and CMCs tend to exhibit similarities in behavior while the HPMCs and MCs 
tend to be paired. 
The results of the ANOVA reinforce these differences and trends. HPMC E had significantly 
higher release than all other compounds. The other HPMCs (with the exception of HPMC 7, which was 
significantly lower than all compounds) had significantly release than all the HECs, CMCs 4 and 5, and 
MC A. CMC 7HF and MC 6 had the same statistical significance as the HPMCs. CMCs 4 and 5 had 
significantly higher release than all the HECs, and MC A had higher release than all the HECs except 
HEC 3. Further, HECs 1 thru 4 had significantly higher release than Nat. 
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 Figure 4.3: Release of tenofovir from cellulose ether solutions. Bars represent means of triplicate 
measurements and error bars represent standard deviations. 
 
Once again, type of substituent group appears to be the most important structural factor 
influencing amount of tenofovir released. The HECs release the least tenofovir, while on average the 
CMCs release an intermediate amount, and the HPMCs and MCs release the most. There are a few 
exceptions to this trend, HPMC 7 and MC A. These data will be discussed more fully in the next section. 
There appears to be no compelling reason as to why they are substantially lower than the other HPMCs 
and MCs. MC A has the same molecular structure as MC 6 and the same molecular weight as HPMCs 8, 
E, F, and K. HPMC 7 has the same structure as HPMC 8 at a lower molecular weight. Although, as 
already pointed out, such a decrease in molecular weight did not impact any of the other compounds to 
such an extent. Overall, the data indicate a progression from least to most amount of tenofovir released as 
the substituent type changes from HEC to CMC to HPMC and MC. This trend becomes even clearer if 
the outlier points are disregarded. 
4.3.3 QSPRs 
 The generation of QSPRs using the drug compatibility data began by considering the solubility 


















































solubility and molecular structure. Type of substituent group seems to be the dominate effect. There is a 
large difference in solubility based on substituent group with CMCs displaying the highest solubility, 
HECs and MCs displaying a similar moderate solubility, and HPMCs displaying the lowest solubility. 
There also appears to be a slight inverse dependence of solubility on molecular weight. After the 
identification of these trends, a correlation was attempted. 
 Since there did not appear to be a clear power, exponential, or logarithmic dependence of 
tenofovir solubility on any of the molecular descriptors, a linear correlation was attempted. The 
descriptors included molecular weight and the two connectivity indices. The resulting correlation was 
fair, with and r2 value of about 0.86. However, the correlation appeared to be skewed due to a clustering 
of data around similar solubility values. In particular, HPMCs 8, E, F, and K have the same molecular 
weight, similar connectivity indices values, and similar solubility values. For this reason the HPMCs with 
the same molecular weight were averaged, generating an average solubility and average connectivity 
indices. The data were then correlated again with one point replacing the four HPMC points. This 
improved the r2 value to 0.92. This final correlation, labeled s, is shown in Table IV.I below, and the 
predictive model is illustrated in Figure 4.4. The q2 value of 0.86 is fair, though not as high as for some of 
the previous correlations. This may be because three unique descriptors are used to describe solubility, 
rather than one combined parameter as seen in some previous QSPRs. A lower q2 may imply some degree 
of correlation over-fit, but removing any of the descriptors did not improve this value. Still, this 
correlation is adequate for incorporation into the overall predictive model of the optimization problem. 
 The final correlation in the predictive model is generated from the tenofovir release data in Figure 
4.3. Similar to the solubility data, these data did suggest trends relating amount of tenofovir released to 
the molecular structure of the cellulose ether. However, these trends appeared to depend solely on the 
identity of the substituent type. There was no consistent trend relating molecular weight to drug release. 
Instead, drug release increased as substituent type changed from HEC to CMC and finally to HPMC and 
MC. Given this progress, a correlation was attempted. 
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 As always, a linear correlation was attempted first with the molecular weight and two 
connectivity indices serving as molecular descriptors. The resulting correlation was quite poor, with an r2 
value of 0.43. When the data was analyzed with this trend line the reason for this poor r2 became 
apparent. As discussed in the section above, HPMC 7 and MC A appear to be exceptions from the major 
observed trends. This was even more apparent when the correlation was fit over the data. The rest of the 
data fit the trend line quite well while these two points were much too low. As already mentioned, there 
does not appear to be a compelling reason for why these points are so much lower. MC A is similar in 
structure to MC 6 and in molecular weight to HPMC 8, E, F, and K. all five of these compounds have 
similar release values. MC A is expected to have a value similar to these other five but is substantially 
lower. Further, HPMC 7 is much lower than the other HPMCs even though the structure is similar. In this 
case the molecular weight is much lower; however MC 6 has a low molecular weight and yet does not 
have a substantial decrease in amount of tenofovir release. For these reasons, these points were excluded 
from the final correlation. Further, MC 6 was excluded from the final correlation since there was no 
compelling reason why a high molecular weight MC has a low release value and a low molecular weight 
MC has a high release value. Thus the final correlation can only predict the structure of HECs, CMCs, 
and HPMCs with a molecular weight of 86,000 and above. 
 The final correlation relating cellulose ether molecular structure to tenofovir release, labeled r, is 
shown in Table IV.I below and Figure 4.5. By eliminating the two exceptions to trends, the r2 value was 
increased to 0.94, a quite dramatic improvement. It should be noted that the final correlation depends 
solely upon 0χ. The molecular weight and 0χV values did slightly improve the r2 value, however when 
cross-validation was performed the q2 value decreased when either of these descriptors was added to the 
correlation. This implies the correlation is over-fit with these values and is more robust with only one 
molecular descriptor. The improved q2 value implies that a slightly less accurate correlation is much more 
predictive.  
This last correlation will be incorporated with the solubility correlation and the QSPRs from 
previous studies to form an overall predictive model. In the Discussion section this predictive model will 
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be incorporated into an optimization problem formulation to design a microbicide formulation compound 
with ideal rheology, cytotoxicity, inhibition of C. trachomatis, solubility of tenofovir, and release of 
tenofovir. 
Table IV.I: Final QSPRs for Solubility and Release Data. For s the HPMCs with molecular weight = 
86,000 were averaged. For r the MCs and HPMC 7 were excluded. 
 
Correlation r2 q2 
s = 3.109 - 2.901*10-7 MW + 1.117 0χ – 1.471 0χV 0.92 0.86 
r = 193.6 – 11.93 0χ 0.94 0.92 
 Figure 4.4: QSPR fitting solubility data to molecular structure. 
 


































 In this section the formulation and solution of the optimization problem are discussed. The final 
predictive model from the present and previous studies is summarized, including limitations to the 
QSPRs. This is incorporated into an optimization problem formulation, along with a set of structural 
constraints. Target properties are selected and the problem is solved to generate proposed novel candidate 
delivery vehicles structures. 
4.4.1 Optimization Problem Formulation 
 The successful completion of the solubility and release studies generated a set of QSPRs to 
describe tenofovir compatibility behavior. These QSPRs join previously generated correlations from 
Chapter 2 describing rheological properties and correlations from Chapter 3 describing biocompatibility 
and inhibition of C. trachomatis to form the final predictive model for the optimization problem. This 
model is shown in Table IV.II below. There are three QSPRs that describe consistency (m), roughly 
divided by substituent group. There are two QSPRs that describe shear-thinning (n), again roughly 
divided by substituent group. A robust correlation with an acceptably high r2 and q2 value could not be 
generated using these connectivity indices to describe n for MCs and HPMCs. A single QSPR describes 
cytotoxicity, with the correlation relating average substituent group to average cytotoxicity. Two QSPRs 
describe inhibition of C. trachomatis, once again roughly divided by substituent group type. Finally, one 
QSPR each describes solubility of tenofovir in cellulose ether solution and release of tenofovir from 
solution. The release correlation excludes MCs and the low molecular weight HPMC since these data 
were not consistent with the trends established by the rest of the cellulose ethers as summarized in 
Sections 4.3.2 and 4.3.3. It should be noted there is an additional correlation describing the consistency 
behavior of MCs and HPMCs, which was not included in the previous rheology results in Chapter 2. That 
chapter focused on HECs and CMCs because they exhibited consistent, reproducible rheology results for 
all measured properties. Conversely, MCs and HPMCs did not have reproducible values for storage and 
loss modulus. Only their viscosity data was reproducible. For that reason these data were excluded from 
the detailed discussion of trends in Chapter 2 but the resulting correlation is included here. 
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Table IV.II: Final Predictive Model for Optimization Problem. 
Correlation r2 q2 Applicability 
m = -367.1 + 4.355x10-7(MW*C)2+52.37 0χ – 32.22 0χV 0.94 0.93 HECs & CMC 5 
m = 1.7239x10-22(MW*C*0χ)4.6596 0.96 0.95 CMC 4 & 7HF 
m = 2.126 – 2.796x1016 MW-2.9 + 1.366x106 C2.4 0.99 0.92 HPMCs & MCs 
n = 0.9291 -3.862x10-7 MW - 0.2903 C + 0.03714 0χ - 0.04311 0χV 0.93 0.89 HECs & CMC 5 
n = 1.583 – 1.338x10-6 MW – 1.154 C 0.94 0.81 CMC 4 & 7HF 
cyto = 0.04676 0χ – 0.2871 0.997 0.99 All* 
inh = 0.001169(MW)0.4489 0.97 0.95 HECs & CMC 4, 7HF 
inh = 0.07089(MW/(0χ*0χV))0.2454 0.95 0.94 MCs, HPMCs**, CMC 5 
s = 3.109 - 2.901*10-7 MW + 1.117 0χ – 1.471 0χV 0.92 0.86 All** 
r = 193.6 – 11.93 0χ 0.94 0.92 HECs, CMCs, HPMCs*** 
*QSPR was formed by averaging by substituent group. Thus the cytotoxicity values and 0χ values were 
averaged for HECs, CMCs, HPMCs, and MCs, resulting in a correlation with four average points. 
**QSPR was formed by averaging HPMCs at MW=86,000. There were four such compounds that 
clustered around one point and sometimes skewed trends. Thus the 0χ values, 0χV values, and experimental 
data were averaged to generated one combined HPMC with MW=86,000. 
***QSPR excludes MCs and HPMC 7. 
****m = consistency, n = shear-thinning index, cyto = cytotoxicity, inh = inhibition of C. trachomatis, s 
= solubility, r = release 
 
After the generation of the predictive model, the next step is to identify target values for all the 
physical properties measured. From Equation 4.1, the goal of the optimization problem is to minimize the 
difference between these target property values and property values predicted by the QSPRs. Table IV.III 
below shows these target values based on different patient groups and treatment arms. The target values 
for consistency and shear-thinning were taken from concurrent thin film flow experiments provided by a 
colleague in Dr. Sarah Kieweg’s laboratory, Sunil Karri (245). Those computational models simulated 
thin film flow between elastic surfaces, analogous to the flow of a viscoelastic fluid in the human vagina. 
A parametric study was then performed on those results to identify the rheological properties that 
corresponded to ideal spreading behavior. For this current study two sets of target rheological properties 
were selected from those simulation results, corresponding to two ideal spreading behavior cases. In those 
simulations, an average vaginal length of 15 cm was assumed, along with a fluid application time of 100 
sec. Further, women were grouped into different patient cases based on vaginal tissue elasticity. In 
particular, vaginal childbirth greatly reduces this elasticity (246). Nulliparous women, women who have 
never given birth, were assumed to have a vaginal elasticity of 50 kPa (247), while multiparous women, 
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women who had multiple vaginal births, were assumed to have a vaginal elasticity of 10 kPa (248). The 
corresponding target values for consistency and shear-thinning are in Table IV.III. 
The other target properties are separated between microbicide and placebo formulations. All cases 
should strive to minimize cytotoxicity as close to 0% as possible. However, inhibition of C. trachomatis 
varies between microbicide and placebo. The delivery vehicle for the microbicide should ideally also non-
specifically inhibit C. trachomatis infection, as close to 100% as possible. Conversely, the delivery 
vehicle placebo, which contains no API, should not inhibit HIV infection or any other STI. Thus the 
delivery vehicle placebo should have an inhibition rate as close to 0% as possible. Finally, for the 
microbicide delivery vehicle the solubility and release of tenofovir should be maximized. A value of 100 
µg was chosen as the release target since this value was well above all the values observed experimentally 
in the above solubility study. A value of 1 mg/mL was chosen for the solubility because this was the 
solubility of the 1% tenofovir gel used in the partly successful CAPRISA 004 study (128). This solubility 
value was a minimum requirement and all solubility values predicted above that value were considered 
acceptable. 
In all there were four different treatment cases. These corresponded to two treatment arms: 
microbicide formulation or placebo, and two patient cases: nulliparous or multiparous. Thus the four 
treatment cases are nulliparous microbicide, nulliparous placebo, multiparous microbicide, and 
multiparous placebo. 
Table IV.III: Target Values for Optimization Problem. 
Physical Property Target Value Comment 
Consistency (m) 250-300 (275)* Nulliparous Case 
Consistency (m) 50-100 (75)* Multiparous Case 
Shear-thinning (n) 0.4-0.5 (0.45)* Nulliparous Case 
Shear-thinning (n) 0.9-1.0 (0.95)* Multiparous Case 
Cytotoxicity 0% All Cases 
Inhibition C. trachomatis 100% Microbicide 
Inhibition C. trachomatis 0% Placebo 
Tenofovir Solubility Maximize (≥ 1 mg/mL) Microbicide 
Tenofovir Release Maximize (100 µg) Microbicide 
*Values obtained from (245). 
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Finally, the above QSPRs and their corresponding target properties were incorporated into an 
optimization problem formulation. To complete the optimization problem, a number of structural 
feasibility constraints were included. The structural parameters include average molecular weight, 
solution concentration, type of substituent group, and amount of substitution. The limitations imposed 
upon these parameters are shown in Table IV.IV below. The molecular weight of the cellulose ethers 
depends upon the chain length of the cellulose raw material, and has an upper limit. The molecular weight 
was constrained within and slightly above the range of the model building set. The concentration range 
roughly represents the range used in the rheology studies. The type of substituent group is limited to the 
four that appear in the correlations. Finally, the amount of substitution was limited based on the type of 
substituent group. A cellulose strand with 10 glucose repeat units, corresponding to a total of 30 
substitution sites, was used to model the substituent effects. Since carboxymethyl and methyl groups do 
not form side chains, the maximum number of substitutions for these groups was 30, while hydroxyethyl 
and hydroxypropyl, which can form side chains, have no upper limit. Additionally, a lower limit to side 
chain substitutions was established. This is because cellulose is insoluble in water, but becomes soluble at 
some threshold. This threshold (249) is different for each substituent type based on polarity and ionic 
nature, as shown in Table IV.IV below. With these values determined and incorporated into the problem 
formulation, the optimization problem can finally be solved to generate novel molecular structures. 
Table IV.IV: Structural Feasibility Constraints. 
Structural Property Limiting Range 
Average Molecular Weight 0-2,000,000 g/mol 
Concentration 0.001-20% 
Type of Substitution Hydroxyethyl (or) Carboxymethyl (or) Methyl (and/or) Hydroxypropyl 
Number of Substitutions: HEC ≥ 5 
Number of Substitutions: CMC 30 ≥ CMC ≥ 4 
Number of Substitutions: MC 30 ≥  MC ≥ 12 
Number of Substitutions: HPMC ≥ 1 
 
4.4.2 Optimization Problem Solution 
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 The optimization problem was formulated to minimize Equation 4.1. It was subject to the QSPRs 
that form the property prediction model in Table IV.II, the target property values in Table IV.III, and the 
structural feasibility constraints in Table IV.IV. This problem takes the form of a mixed-integer nonlinear 
program (MINLP). This is because the property prediction model has both linear and non-linear QSPRs 
and the number of possible substituent groups of each type is an integer. This problem was written in 
GAMS software and solved using the DICOPT solver. Further, the code was separated into five different 
problem formulations based on type of substituent group, one for HECs, MCs, and HPMCs, and two for 
CMCs. This method is similar to one employed by Harper and Gani (250) who stipulated that for a 
MINLP problem in which the number of binary integers is small and can be enumerated, that a NLP 
problem can be solved for each set of binary variable values. The separation performed of the MINLP 
based on substituent type in this current dissertation lowers the integer decisions in the problem solution 
from two to one, allowing for more robust deterministic solution of the simplified MINLP problem. 
Each of these problem formulations had a single QSPR from Table IV.II for each of consistency, 
shear-thinning, cytotoxicity, C. trachomatis inhibition, and tenofovir release for a total of five 
correlations. The appropriate QSPR for each property was selected to correspond to the substituent type 
of the problem formulation and was subject to the structural feasibility constraints unique to that 
substituent type. For example, the HEC problem formulation was subject to the first consistency, shear-
thinning, and C. trachomatis inhibition QSPRs in Table IV as well as the overall cytotoxicity and release 
QSPRs. The number of substituent groups for the HECs was limited to ≥ 5. 
This formulation scheme was repeated for the MCs and HPMCs and done twice for the CMCs 
since the data for these cellulose ether types are divided among two sets of QSPRs, with one predictive 
model for DS≤0.9 and one predictive model for DS≥1.2. The separation was carried out to allow for the 
generation of candidate molecular structures for each substituent type. Preliminary observations of the 
data gathered in the rheology, biocompatibility, and drug compatibility studies indicated that the HPMCs 
and MCs might dominate the solution space, since these compounds had lower cytotoxicity and higher 
release than the HECs and CMCs on average. Thus the separation of the problem formulation was carried 
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out to ensure the generation of candidate molecular structures for HECs, CMCs, HPMCs, and MCs for 
comparison purposes to verify if the assumption about the above trends in physical properties was indeed 
true. 
 The optimization problem formulations were solved multiple times for each substituent type. The 
best molecular candidates for each substituent type as well as the four possible treatment cases are 
reported in Table IV.V below. For this current optimization problem, the best structures are defined as 
those structures that have m and n values within the target ranges, solubility values above 1 mg/mL, and 
the lowest cytotoxicity values. Further, if the candidate structure is for the microbicide formulation it has 
the highest release and the highest C. trachomatis inhibition values. If the candidate molecule is for the 
placebo then it has the lowest C. trachomatis inhibition value. Structures that possessed values outside of 
the consistency and shear-thinning range presented in Table IV.III were rejected. Further, solubility was 
not included as a parameter in the optimization problem formulation. This was because solubility had a 
somewhat inverse relationship with release in that release increased as amount of substitution decreased 
while solubility tended to decrease. Release was deemed the more important property of the two. Thus 
solubility was used as a post-optimization check, and candidate structures with a predicted solubility ≤ 1 
mg/mL were rejected. 
Table IV.V: Candidate Molecular Structures for Novel Delivery Vehicles. 
Delivery Vehicle for Nulliparous Microbicide 
Property HEC CMC (≤0.9) CMC (≥1.2) HPMC MC 
MW 1,486,000 868,000 1,572,000 1,000,000 1,000,000 
c 1.92% 1.91% 1.58% 2.87% 2.87% 
0χ 9.11 9.25 11.64 9.20 8.90 
0χV 6.68 6.55 8.11 7.19 6.92 
DS or MS 0.5 (MS) 0.4 (DS) 1.2 (DS) 0.1/1.2 1.2 (DS) 
m 250 250 250 275 275 
n 0.4 0.4 0.4 - - 
% inh 68.9% 54.1% 77.0% 75.2% 76.5% 
% cyto 13.9% 36.1% 52.9% 14.3% 12.9% 
r 84.9 µg 83.3 µg 54.7 µg 83.9 µg - 
s 3.03 mg/mL 3.55 mg/mL 3.72 mg/mL 2.51 mg/mL 2.58 mg/mL 
 
Delivery Vehicle for Nulliparous Placebo 
Property HEC CMC (≤0.9) CMC (≥1.2) HPMC MC 
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MW 1,223,000 791,000 1,309,000 13,700 13,700 
c 2.49% 2.18% 2.07% 20% 20% 
0χ 9.11 9.25 11.64 9.20 8.90 
0χV 6.68 6.55 8.11 7.19 6.92 
DS or MS 0.5 (MS) 0.4 (DS) 1.2 (DS) 0.1/1.2 1.2 (DS) 
m 300 300 300 275 275 
n 0.5 0.4 0.5 - - 
% inh 63.2% 51.9% 73.6% 26.2% 26.7% 
% cyto 13.9% 36.1% 52.9% 14.3% 12.9% 
 
Delivery Vehicle for Multiparous Microbicide 
Property HEC CMC (≤0.9) CMC (≥1.2) HPMC MC 
MW 110,000 490,000 251,000 1,000,000 1,000,000 
c 12.9% 2.39% 5.00% 1.66% 1.66% 
0χ 11.87 9.25 11.64 9.20 8.90 
0χV 9.05 6.55 8.11 7.19 6.92 
DS or MS 1.8 (MS) 0.4 (DS) 1.2 (DS) 0.1/1.2 1.2 (DS) 
m 50 50 50 75 75 
n 0.9 0.9 0.9 - - 
% inh 21.4% 41.9% 49.1% 75.2% 76.5% 
% cyto 26.8% 36.1% 52.9% 14.3% 12.9% 
r 52.0 µg 83.3 µg 54.7 µg 83.9 µg - 
s 3.02 mg/mL 3.66 mg/mL 4.10 mg/mL 2.51 mg/mL 2.58 mg/mL 
 
Delivery Vehicle for Multiparous Placebo 
Property HEC CMC (≤0.9) CMC (≥1.2) HPMC MC 
MW 97,000 407,000 63,000 14,000 14,000 
c 14.6% 3.35% 20% 20% 20% 
0χ 11.87 9.25 11.64 9.20 8.90 
0χV 9.05 6.55 8.11 7.19 6.92 
DS or MS 1.8 (MS) 0.4 (DS) 1.2 (DS) 0.1/1.2 1.2 (DS) 
m 50 100 50 75 75 
n 0.9 1.0 0.9 - - 
% inh 20.2% 38.5% 30.8% 26.2% 26.7% 
% cyto 26.8% 36.1% 52.9% 14.3% 12.9% 
 
 These candidate molecular structures reveal many intriguing trends that lead to suggestions for 
next generation delivery vehicles for both microbicides and their corresponding placebos. The physical 
properties had differing degrees of dependency on different molecular descriptors, facilitating a robust 
optimization. Both cytotoxicity and tenofovir release depended solely on substituent group, with 
cytotoxicity decreasing and release increasing with decreased substitution. Luckily, decreasing 
cytotoxicity while simultaneously increasing release were both target properties, so decreasing amount of 
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substitution synergistically improved these predicted properties. For this reason, all the candidate 
molecular structures (except HEC for the multiparous group) have the minimum degree of substitution 
allowed for each substituent type. These optimization results suggest that the most ideal microbicide 
delivery vehicles have the minimum allowable MS/DS values for solubility in the acidic microbicide 
formulation. 
With both cytotoxicity and release influencing amount of substitution, molecular weight and 
concentration were the main descriptors varied to optimize consistency, shear-thinning, and C. 
trachomatis inhibition. Inhibition depended mainly, or for some substituent groups solely, on molecular 
weight. Thus in the constrained optimization problems, those that had QSPRs for both consistency and 
shear-thinning, the goal became to optimize molecular weight while keeping the rheological properties 
within their suggested ranges. Consistency increased with both molecular weight and concentration, while 
shear-thinning decreased as these parameters increased. These antagonist effects limited the acceptable 
range of concentration and molecular weight for the HECs and CMCs. For this reason the range of C. 
trachomatis was limited for these compounds. Conversely, since a predictive shear-thinning QSPR could 
not be generated, the MCs and HPMCs were unbound. Thus, to maximize inhibition for the microbicide 
delivery vehicle the molecular weight can be maximized to the limit of the allowable range while the 
concentration is lowered to maintain consistency at the proper value. To minimize inhibition for the 
placebo, the molecular weight can be lowered to the limit of the allowable range while the concentration 
is raised its limit. Based on this optimization behavior, the molecular weight of the MCs and HPMCs was 
restricted to 1,000,000 g/mol to allow for a more straight-forward comparison with the HEC and CMC 
candidate structures. 
Analyzing all the candidate structures for all four treatment cases allows for recommendations to 
be made for next generation delivery vehicles. In particular, HPMCs appear to be the best candidates. 
These cellulose ethers exhibit low cytotoxicity and high release. Further, C. trachomatis inhibition of 
HPMCs can be varied by a large amount to create a microbicide with high inhibition and a placebo with 
low inhibition. This flexibility is allowed partly due to the inability to create a predictive QSPR 
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describing shear-thinning behavior. However, a parametric study performed by a colleague in Dr. Sarah 
Kieweg’s laboratory, Dr. Md Rajib Anwar (251) of a spreading simulation similar to the one used to 
generated target consistency and shear-thinning values indicated that consistency is much more important 
than shear-thinning. That study indicated that shear-thinning can vary over most of the range between 0 
and 1.0 without having much of an impact on spreading behavior. However, it should be noted that a 
Herschel-Bulkley fluid with a yield stress was used in that study instead of the power-law fluids used 
throughout this dissertation. Thus, shear-thinning might be negligible compared to consistency and yield 
stress in a Herschel-Bulkley fluid but shear-thinning might not be negligible compared to just consistency 
in a power-law fluid. Even with this limitation, the HEC and CMC optimization problems were repeated 
with the shear-thinning eliminated as a constraint. As in the case of the MCs and HPMCs, this allowed 
these problems to become unbound and percent inhibition could vary over a much greater range while 
consistency was maintained at its target value. Even with this much greater degree of freedom for all the 
cellulose ethers, HPMCs continued to have candidate structures with more ideal properties than the other 
substituent types. 
As discussed above, CMCs are not recommended for use as either a microbicide or placebo 
formulation because of their higher cytotoxicity compared to the other substituent types. The lowest 
allowable CMC degree of substitution (DS=0.4) has a predicted cytotoxicity of 36%. This is not a high 
value, but the microbicide formulation ideally will be used with every sexual encounter, possibility 
multiple times per day, for years. A chronic low level cytotoxicity could irritate the vaginal epithelium, 
cause micro-abrasions, and facilitate entry of HIV and other STIs. This harm would invalidate any benefit 
of the formulation conferred by the API. Further, because CMCs 4 and 7HF have a steeper dependence 
upon molecular weight than the other cellulose ethers, the maximum allowable molecular weight to 
maintain the target consistency is lower, which in turn lowers C. trachomatis infection. CMC 5 does have 
a lower dependence upon molecular weight, allowing for larger molecular weight CMCs with much 
higher percent inhibition. However, these CMCs have a much higher DS and thus a much higher 
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cytotoxicity. This is an undesirable tradeoff, and thus CMCs should be avoided as vaginal delivery 
vehicles in favor of other cellulose ethers. 
The removal of CMCs from consideration leaves the HECs, HPMCs, and MCs. The MCs are also 
removed from further consideration. Although MCs have slightly better C. trachomatis inhibition and 
solubility than comparable HPMCs, they do not exhibit predictable release behavior and thus cannot be 
optimized for with as high a degree of certainty as the other cellulose ethers. This leaves the HECs and 
HPMCs. Reviewing the nulliparous microbicide case in Table VII indicates that HECs and HPMCs have 
very similar ideal properties. For a similar range of consistency and shear-thinning values, HECs and 
HPMCs have very similar values of cytotoxicity, C. trachomatis inhibition, and release. Further, HECs 
have slightly higher tenofovir solubility. When HEC optimization is unconstrained by shear-thinning, the 
ideal properties for the other three treatment cases become very similar between the HECs and HPMCs. 
However, a closer inspection will reveal HECs have similar ideal properties to HPMCs because the 
optimization allowed them a greater range of molecular descriptors. Only by lowering the HECs to the 
theoretical limit of their solubility (MS=0.5) did the cytotoxicity, inhibition, and release values reach 
those of the HPMCs. The multiparous HEC with an MS closer to that observed in the model building set 
(MS=1.8) had much lower inhibition and release, and slightly higher cytotoxicity, when compared to the 
multiparous HPMC. Further, for the nulliparous case, the HEC only had comparable properties to the 
HPMC because the molecular weight was allowed to vary over a greater range. At a comparable 
molecular weight an HPMC has an inhibition of C. trachomatis approximately 20% higher than an HEC. 
Based on the predictive capability of the QSPR model and the cytotoxicity, HECs and HPMCs are 
preferable to MCs and CMCs. While both HECs and HPMCs are applicable as microbicide and placebo 
formulations, HPMCs are slightly more favorable. 
4.5 Conclusions 
 The completion of this final study indicates the successful completion of a computational 
molecular design problem. This study successfully measure solubility and release of tenofovir in a model 
building set of cellulose ether compounds. These property data were successfully correlated with 
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molecular structure descriptors to create a predictive QSPR model that related the molecular structure of 
most cellulose ethers to drug compatibility. This predictive model was successfully combined with the 
predictive models from previous studies. Thus an overall predictive model was created that related 
molecular structure to rheology, biocompatibility, and drug compatibility. This overall predictive model 
was successfully integrated into an optimization problem formulation. Target properties were successfully 
identified based on the observations in the present studies and concurrent thin film flow studies. 
Structural feasibility constraints were obtained from literature sources and experimental observations 
from this and previous studies. These target properties and structural constraints were incorporated along 
with the QSPRs to generate the final optimization problem formulation. Finally, this optimization 
problem was solved in GAMS several times to create novel candidate microbicide and placebo structures 
for different groups of women. 
 The optimization problem was solved to generate many feasible molecular structures to serve as 
vaginal delivery vehicles. These candidates have predicted properties for a wide range of applicable 
microbicide properties. Many of the predicted structures have improved behavior compared to the 
currently used “Universal Placebo.” In addition, the segregation and solution of the optimization problem 
by substituent type revealed several trends to inform future microbicide development. Minimizing MS/DS 
to the limit of solubility generally results in lower cytotoxicity and higher drug release. Increasing 
molecular weight increases C. trachomatis infection. One cellulose ether with a unique MS/DS can be 
selected for each treatment case. A high molecular weight can be selected for the raw material. The 
molecular weight can then be shortened to service both nulliparous and multiparous women. The 
molecular weight can be further shortened and the cellulose ether concentration can be increased to create 
a placebo with similar properties to the microbicide delivery vehicle except with lower C. trachomatis 
infection. The CMCs should be avoided for their higher cytotoxicity compared to the other cellulose ether 
types. HECs, HPMCs, and MCs are all acceptable delivery vehicles. However, MCs have less predictable 
behavior, and at comparable molecular weight and degree of substitution, HPMCs have more ideal 
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properties compared to HECs. Thus HPMCs are recommended for further evaluation and incorporation as 
delivery vehicles into next generation microbicides.  
 The success completion of this study serves to validate the use of computational molecular design 
to rationally design vaginal microbicide delivery vehicles. The techniques outline in this and the previous 
studies can be expanded. More physical properties, such as mucoadhesion can be considered to create an 
ever more robust optimization problem formulation. This allows for the generation of candidate 
microbicides with even more specific activity. This methodology can be used to design compatibility with 
other APIs or other tissue systems, such as rectal microbicides. Other cell cytotoxicities, drug solubility 
and release profiles, and non-specific inhibition of STIs can be correlated with molecular structure and 
incorporated into the present optimization problem formulation. This methodology can be repeated for a 
new model building set for a new class of delivery vehicles for vaginal, rectal, or dermal delivery. Finally, 
this CMD methodology can be expanded to other pharmaceutical fields to rationally design delivery 
vehicles and drugs for a wide array of purposes. By repeated solution of similar optimization problem 
formulations, properties that limit molecular structure can be identified, as was done in the present case. 
Critical molecular structure descriptor values can be identified. Additionally, the properties identified in 
the predictive model can be weighted differently to evaluate which are more important to ideal 
performance than others. These methods combined with high-throughput screening could lead to more 
streamlined and improved drug and formulation discover in the field of vaginal microbicides as well as 










Discussions and Conclusions 
 There remains a pressing need for female-controlled prevention tools to protect against 
HIV/AIDS. Topical microbicides with “gel” delivery vehicles have undergone the most extensive 
characterization and clinical evaluations. They have also been responsible for some of the most 
significant failures in the field of microbicide clinical trials, whether by failing to prove efficacy or by 
causing outright harm. This indicates a need to establish a methodology to rationally design delivery 
vehicles with better understood and more ideal properties. An ideal microbicide must be safe to use, 
effective against HIV, and acceptable to the patient. A number of large scale clinical trials have failed to 
prove efficacy against HIV by failing to exhibit one or more of these characteristics. Thus these 
characteristics should be evaluated at the pre-clinical stages and next generation delivery vehicles should 
be designed to encompass all these properties. The present study considered several properties relating to 
these three necessary characteristics. Safety was described by in vitro cytotoxicity and inflammation. 
Efficacy was described by solubility of the microbicide, release of the microbicide, and non-specific 
inhibition of C. trachomatis. Patient acceptability was related to rheological properties. CMD was used to 
design candidate delivery vehicles that considered each of these properties when creating novel structures. 
The culmination of this entire study, including the rheology study in chapter 2, the biocompatibility and 
inhibition study in chapter 3, and the solubility and release study as well as optimization solution in 
chapter 4, represents the successful application of the CMD methodology to the field of topical vaginal 
microbicide “gels.”  
5.1 Discussion of Rheological Study 
The study of rheological properties in chapter 2 sought to describe the rheology of a variety of 
delivery vehicles, restricted to cellulose ethers for the entirety of the whole study. Previous studies had 
looked a rheology of one or a few cellulose ethers, but none had compared such a large number of these 
compounds to each other. This study successfully measured the rheology of individual cellulose ethers at 
various concentrations. The data revealed intriguing trends relating these measured properties to 
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molecular weight, concentration, and substituent effects. Further, these trends provided insight that 
allowed for the successful generation of a set of nonlinear QSPRs that accurately predicted rheological 
behavior based on molecular structure. The completion of this first study was highly encouraging for the 
completion of the subsequent studies in that differences in physical properties were observed based on 
differences in identity of cellulose ether, and further that these differences could be numerically 
described. 
Although the first rheology study was successful in both creating a predictive model describing 
rheological properties based on molecular structure and providing a framework for the other studies in 
chapters 3 and 4, analysis of this data did present several limitations. The first that must be mentioned is 
that rheology data for the HPMCs and MCs evaluated in the biocompatibility, inhibition, and drug 
compatibility studies are not presented in chapter 2. This is because no consistent storage and loss 
modulus data for the HPMCs and MCs could be measured. These data are obtained by performing 
oscillatory frequency sweeps at a constant stress in the linear viscoelastic regime over a range of 
frequencies. However, for the range of stresses measured by the instrumentation, the HPMCs and MCs 
did not exhibit a linear regime. Instead, these data took on a sigmoidal shape. Without a linear regime the 
results of these frequency sweeps varied widely depending on the stress chosen. For this reason the 
HPMC and MC rheology data were not presented in chapter 2 and the correlations for G’ and G” were 
excluded from the final optimization problem formulation in chapter 4. Further, concurrent thin film flow 
studies did not suggest ideal target values of G’ or G” to optimize for, providing another reason to 
exclude these correlations from the final optimization problem formulation. Thus the final QSPR model 
in chapter 4 cannot predict elastic behavior of cellulose ether solutions. 
Another major limitation found in the rheology study in chapter 2 is that no single QSPR could be 
generated to a high degree of accuracy or predictive capability to describe all the cellulose ether solutions 
measured. The final rheological predictive model had to be divided into three correlations for consistency 
and two for shear-thinning according to side chain substituent type. Further, no correlation could be 
generated to describe the shear-thinning behavior of HPMCs and MCs according to their molecular 
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structure. Although this segregation of data represents a major limitation in the rheology study in chapter 
2, it does reveal an interesting trend in rheological properties of cellulose ethers based on substituent type. 
The rheological properties of all cellulose ether solutions increase nonlinearly to some power 
with molecular weight and concentration. However the steepness of this nonlinear variation differs greatly 
between HECs, CMCs, and HPMCs/MCs. The study in chapter 2 showed two distinct trends separating 
the HEC and CMC consistency data. The CMCs (excluding CMC 5) have a much steeper dependence 
upon molecular and concentration compared to the HECs. This means they have much higher consistency 
values at similar molecular weights and concentrations compared to the HECs. Although not shown, the 
HPMCs and MCs exhibit a trend separate from both the HEC and CMC trends. This HPMC/MC trends is 
even steeper than the other two trends, indicating an even greater consistency at comparable molecular 
weights and concentrations. The exception to these general trends is CMC 5, which exhibits rheology 
comparable to HECs instead of CMCs. This indicates there might yet be another factor besides identity of 
substituent type, molecular weight, and concentration of cellulose ether solutions that influences their 
rheology. 
The need to segregate rheology data in order to create an accurate predictive model indicates the 
present molecular descriptors might not be wholly appropriate for the present optimization problem 
formulation. Future work should consider other molecular descriptors to describe the side chain 
substitutions to see if these more accurately describe differences in rheological properties based on 
molecular structure. 
Even with these limitations, the successful completion of the rheology study provides useful data, 
trends, and a predictive model. This predictive model was incorporated into the final optimization study 
in chapter 4 to design candidate microbicides and placebos with target consistency and shear-thinning 
correlated with applicability to different patient populations. These data and this predictive model can be 
useful to many diverse pharmaceutical fields and industrial industries. The type of cellulose ether can be 
selected based on the desired range of rheological properties and the molecular weight and concentration 
can be varied to produce solutions with precisely desired consistency and shear-thinning behavior. 
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5.2 Discussion of Biocompatibility and Inhibition Study 
The study of in vitro biocompatibility and inhibition in chapter 3 sought to describe the 
cytotoxicity, inflammation production, and C. trachomatis inhibition conferred by the set of cellulose 
ethers. Once again, previous studies had considered one or a few of these properties for microbicide APIs 
and one or a few delivery vehicles. However, extensive safety data for cellulose ethers was lacking, 
chiefly because as excipient compounds they are assumed biologically inert. This study successfully 
measured these properties for 15 cellulose ethers at constant concentration and the data revealed 
interesting trends that challenged this long held assumption. Further some of these data were incorporated 
into a set of QSPRs that predicted degree of cytotoxicity and inhibition of C. trachomatis based on 
identity or the molecular weight of the cellulose ether. 
Although not all of the biocompatibility data exhibited enough variation to incorporate into a 
QSPR, the completion of this study was perhaps even more successful than the previous rheology study. 
Prior to completion of that study different cellulose ethers were known to have different rheological 
properties. However, cellulose ethers were assumed to have the same negligible biocompatibility and 
inhibition properties. Luckily for clinical applications this assumption proved true for inflammatory 
cytokine production. However, the cytotoxicity study indicated that some cellulose ethers, in particular 
the ionic CMCs, might cause some harm to native tissues. Further, the inhibition study indicated that 
different cellulose ethers confer different non-specific inhibition of C. trachomatis infection, highly 
correlated with increased molecular weight, which in turn is highly correlated with consistency.  
The above described cytotoxicity and inhibition data were successfully incorporated into a set of 
accurate and predictive QSPRs that describe these properties based on molecular structure. These QSPRs 
were successfully integrated into a predictive model in the final optimization study in chapter 4 to 
generate candidate delivery vehicles with predicted cytotoxicity and inhibition. However, similar to the 
rheology study in chapter 2, these QSPRs had a number of limitations. 
The first major limitation pertains to the cytotoxicity QSPR. The measured cytotoxicity data 
displayed no consistent variation due to changes in molecular weight or alterations in the MS/DS. The 
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only consistent difference exhibited by these data correlated with identity of substituent group. CMCs 
were more cytotoxic than HECs, which, on average, were more cytotoxic than HPMCs and MCs. The 
lack of correlation with molecular weight or MS/DS produced correlations with poor fit when all the data 
were considered separately. A highly predictive correlation could only be generated when the data based 
on substituent type were averaged. Thus cytotoxicities of the CMCs, HECs, HPMCs, and MCs were 
averaged and their molecular structure was represented by an average connectivity index to indicate each 
type of substituent group. This allowed for a correlation that could accurately predict the type of 
substituent for a given candidate cellulose ether, but not the required molecular weight or MS/DS or that 
cellulose ether. 
Further, statistical analysis of the cytotoxicity data revealed that with the large standard 
deviations exhibited in the data, only differences of about 25% were statistically significant. This informs 
interpretation of the optimization problem. Candidate structures with cytotoxicity up to 25% are not 
statistically significantly different from zero cytotoxicity. Candidate structures with cytotoxicity values 
within 25% of each other are not statistically significantly different from each other. Thus only high 
cytotoxicity values, such as the 40-50% conferred by CMCs, are significant to the design of a novel 
candidate structures. 
A second major limitation is the groupings required to generate a predictive QSPR model to 
describe C. trachomatis inhibition. These data could not be described in a single, accurate QSPR. Rather 
two QSPRs, one for all the HECs and CMCs 4 and 7HF and one for all the HPMCs, MCs, and CMC5, 
had to be generated. Further, while all the data was used for the HEC/CMC QSPR, for the remaining 
QSPR most of the HPMC data had to be averaged. This was because there were four HPMCs with the 
same molecular weight and similar connectivity indices values, comprising the only molecular descriptors 
available for generate of the QSPR. The cluster of four data points around one point skewed the 
correlation and lowered the accuracy. For this reason these points were averaged. This creates a 
correlation that can accurately predict the molecular weight and identity of a novel cellulose ether 
structure. However, it cannot accurately predict the exact MS/DS of a generated HPMC. The correlation 
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can indicate that the novel structure should be a HPMC, but not what the MS/DS should be. This adds an 
additional limitation to the scope of the optimization problem solutions. 
Both cytotoxicity and inhibition are vital when designing a delivery vehicle and placebo for HIV 
microbicides. A harmful delivery vehicle could increase clinical trial failure by disrupting the vaginal 
epithelium and promoting viral penetration, invalidating any positive benefit conferred by the API. 
Conversely, a delivery vehicle that non-specifically inhibits C. trachomatis, an STI that once obtained 
significantly increases a patient’s risk of HIV infection when exposed, could boost the efficacy of a 
microbicide, or cause clinical trial failure if the placebo is more effective against C. trachomatis than the 
microbicide delivery vehicle. These results provide promising trends that provide insights that future 
studies should expand upon. The marginal cytotoxic and inhibitory effects described in the study in 
chapter 3 might explain some of the resent clinical trial failures, such as cellulose sulfate, which used 
ionic cellulose as the API and exhibited harm in some clinical trial, and PRO 2000, which used a different 
delivery vehicle in the microbicide formulation and placebo. 
5.3 Discussion of Solubility and Release Study 
 The study of drug compatibility properties in chapter 4 sought to describe the solubility of 
tenofovir in and release of tenofovir from the model building set of 15 cellulose ethers. Previous studies 
would consider the solubility and release of one or a few drugs in one or a few excipients. Extensive data 
of these properties was lacking for cellulose ethers. Most studies would select an API and delivery 
vehicle, measure the solubility and release, and report these values without trying to maximize either 
property. Such tactics are acceptable for water soluble drugs such as tenofovir, but prove challenging for 
other APIs with less hydrophilic behavior. This study provides a framework to assess these properties that 
can be expanded to other, more challenging APIs. This study successfully measured solubility and release 
for tenofovir in cellulose ethers at constant concentration. Once again, as seen in the previous studies in 
Chapters 2 and 3, these data provided interesting trends relating these properties to molecular structure. 
These data were successfully incorporated into a set of QSPRs that predicted solubility based on all 
molecular descriptors and release based on substituent type. These QSPRs served as the final portion of 
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the predictive model that was incorporated into the optimization problem formulation in the final study 
and solved to generate candidate delivery vehicles. 
 Both solubility and release were successfully correlated with molecular structure. Although this 
behavior had not been explicitly described in previous studies, some trends could be assumed based on 
molecular structure. In particular, more hydrophilic compounds such as CMCS and HECs were assumed 
to confer increased solubility to hydrophilic tenofovir compared to more hydrophobic HPMCs and MCs. 
In a related manner, the release behavior was assumed to be exactly the opposite of the solubility behavior 
as the hydrophilic compounds would resist releasing the hydrophilic API while the hydrophobic 
compounds would facilitate this process. The experimental results somewhat supported these hypotheses. 
In particular the CMC solubility was much higher than all the other compounds. The HECs were higher 
than most HPMCs, but were unexpectedly comparable to the MCs. In contrast, the release was the highest 
for the HPMCs (except HPMC 7). The HPMCs were higher than the CMCs (comparable to CMC 7HF) 
and the CMCs were higher than the HECs. This is not a complete inverse of the solubility as predicted. 
While the HPMCs had the lowest solubility and highest release, the CMCs had the highest solubility and 
intermediate, not the lowest, release. 
 The solubility and release data were successfully incorporated into accurate and predictive 
QSPRs that complemented predictive models from the studies in Chapters 2 and 3. However, once again 
these QSPRs had a number of significant limitations. All the data points were used to generate a linear 
correlation describing solubility data. Similar to the inhibition QSPR, the four HPMCs with the same 
molecular weight and similar MS/DS values had to be averaged to overcome the clustering at one point in 
the graph that lowered r2. This solubility correlation can accurately predict molecular weight and 
substituent type. For HECs, CMCs, and MCs this correlation can accurately predict MS/DS as well. Due 
to the average for HPMCs, this correlation can only indicate that a candidate cellulose ether should be a 
HPMC and not what the exact MS/DS should be. This limitation restricts predictive capability of the final 
optimization problem solution. 
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 A final major limitation pertains to the release QSPR. To generate an accurate and predictive 
QSPR using this data, some data points had to be omitted. In particular HPMC 7 and MC A were 
appreciably lower than the other HPMCs and MC. There was no structural basis for this behavior. Thus to 
ensure the generation of a robust QSPR these points were omitted from the final correlation. MC 6 was 
also omitted because there was no compelling reason to include this MC if the other was excluded. This 
resulted in a final release correlation that could accurately predict the MS/DS of HECs, CMCs, and 
HPMCs with a molecular weight of 86,000 and greater. However, this correlation could not predict 
HPMCs with a lower molecular weight and could not predict MCs at all. This created the major limitation 
that MCs could not be designed to have optimal release. 
5.4 Discussion of Optimization Study 
 The final study in chapter 4 sought to incorporate all the QSPRs from the previous rheology, 
biocompatibility, inhibition, and drug compatibly studies into a final predictive QSPR model. This 
predictive model was incorporated, along with some structural feasibility constraints, into an optimization 
problem formulation and then successfully solved to generate novel cellulose ether candidate structures 
with ideal physical properties. By varying molecular weight, type of substituent group, MS/DS, and 
concentration, the above physical properties could be designed to have improved or even ideal target 
properties. The successful completion of this study validates the use of CMD methodology to rationally 
design next generation microbicide delivery vehicles. 
The optimization problem was solved for four different treatment groups, including two different 
groups of women that required different rheological properties, and the microbicide delivery vehicle and 
placebo which require maximizing and minimizing inhibition, respectively. In all cases the optimization 
problem sought to minimize degree of substitution since doing so maximized both release and minimized 
cytotoxicity. With these two physical properties restricting the connectivity indices, target rheological 
properties were achieved by altering molecular weight and concentration. 
By solving the optimization problem uniquely for each type of substituent group, interesting 
trends in the solution space were observed. In particular, CMCs were not ideal since they exhibited 
99  
significantly higher cytotoxicity than the other substituent group types. Attempting to minimize this 
cytotoxicity by reducing DS resulted in decreased tenofovir release compared to the other substituent 
group types, which was not ideal. MCs were also not ideal since the lack of their integration into the 
release QSPR restricted the predictive ability of the optimization solution. MCs could be designed for low 
cytotoxicity and inhibition which might make them desirable for placebo formulations. HECs and 
HPMCs both generated favorable delivery vehicle structures with comparable high release, high 
inhibition, and low cytotoxicity. One intriguing trend suggested that HPMCs were actually the most 
favorable delivery vehicles. At comparable molecular weights HPMCs higher inhibition of C. 
trachomatis compared to HECs. This implies for HPMCs that the DS could be lowered to the limit of 
cellulose ether solubility and the molecular weight could be maximized to maximize inhibition while the 
solution concentration is altered to maintain optimal rheological properties. 
Another interesting trend was observed when comparing the nulliparous and multiparous 
candidate structures. These patient cases had the same target values for all physical properties except 
rheology. Specifically, multiparous structures had lower consistency and higher shear-thinning indices 
compared to nulliparous structures. Observing the nulliparous and multiparous microbicide cases reveals 
the impact changing viscosity has on the other physical properties. These viscosity parameters depend 
heavily on molecular weight and concentration. Cytotoxicity and release depend mainly on substituent 
type and MS/DS and are thus very similar for both the nulliparous and multiparous cases. However, 
inhibition of C. trachomatis depends heavily on molecular weight and thus changes a great deal with 
changing consistency. Thus formulations with higher consistency have higher C. trachomatis inhibition. 
This could be a useful correlation to exploit, especially if consistency and shear-thinning indices could be 
adjusted while maintaining similar spreading behavior. Thus a microbicide formulation could be 
developed with a higher consistency to have higher inhibition of C. trachomatis. Conversely, a placebo 
formulation could have a lower consistency to have lower inhibition of C. trachomatis while maintaining 
similar spreading behavior to the microbicide formulation. 
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This optimization problem does have number of limitations that limit its predictive capability. 
The restrictions on the QSPRS generated in Chapters 2, 3, and 4 apply and limit how accurately some 
types of cellulose ethers can be predicted. In particular, several correlations predict that a cellulose ether 
should be a HPMC but do not predict its exact MS/DS since these correlations were generated using 
average HPMC values with average connectivity indices. As discussed above, a major limitation is that 
the release behavior of MCs cannot be predicted and thus these cellulose ethers cannot be fully evaluated 
for the prediction of a delivery vehicle, although they can accurately predict a placebo.  
As described in Chapter 3, the cytotoxicity correlation is only an average for each substituent 
group. This correlation can predict cytotoxicity based on the identity of the cellulose ether but cannot be 
used to design for specific MS/DS. This correlation instructs the optimization problem to minimize 
cytotoxicity by minimizing a connectivity index and thus minimizing MS/DS. However, this correlation 
does not accurately correlate to MS/DS. Thus the predicted structures in Chapter 4 with low cytotoxicity 
due to low MS/DS might in reality have slightly higher cytotoxicity values. 
A final major limit is due to the fact that the shear-thinning correlations could be generated from 
the HEC and CMC data, but not the HPMC and MC data. This is of particular concern because when 
solving the optimization problem the antagonistic molecular weight and concentration behavior of the 
consistency and shear-thinning correlations provided bounds to the HEC and CMC data. These 
compounds could not maximize or minimize their molecular weights or MS/DS to the limits of feasibility 
and maintain consistency and shear-thinning values within the recommended range. This placed 
limitations on the possible HEC and CMC candidate structures that were not placed upon the HPMCs and 
MCs. 
Even with the above limitations, the successful solution of the optimization problem formulation 
did generate candidate molecular structures with more ideal properties than those exhibited by the model 
building set, including the “universal placebo.” This allows for the rational design of new cellulose ethers 
to create improved delivery vehicles and a better placebo. If the shear-thinning requirement can be 
relaxed, the current optimization problem suggested a high molecular weight HPMC with low 
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concentration and low MS/DS would serve as an optimal delivery vehicle for both nulliparous and 
multiparous women. An HPMC with the same MS/DS but low molecular weight and high concentration 
would serve as an optimal placebo in both cases. If this requirement is not relaxed, then HPMCs and MCs 
must be excluded from the design space. This leaves CMCs and HECs. CMCs have unfavorable 
cytotoxicity, so only HECs can be considered when designing an optimal delivery vehicle, as is used in 
the “universal placebo.” Even so, the current predictive model and optimization problem formulation can 
identify the molecular weight, MS, and concentration of an ideal HEC delivery vehicle. That ideal 
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